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of glycemia, and the risk of type 2 
diabetes and cardiovascular events 
were identified.
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ABSTRACT 
 
The prevalence of type 2 diabetes has increased dramatically during the last decades. 
Currently type 2 diabetes affects about 9% of adult population in the world. Insulin 
resistance and impaired insulin secretion are the two major pathophysiological defects in 
type 2 diabetes, which is associated with several metabolic disturbances and increased risk 
of cardiovascular disease. The availability of biomarkers to identify individuals who are at 
increased risk of developing type 2 diabetes is of great importance. The main aim of this 
study was to identify markers of glycemia (tissue-specific insulin resistance) and 
dyslipidemia (lipids, lipoproteins, apolipoproteins) to predict development of type 2 
diabetes, worsening of glycemia and cardiovascular events in the prospective population-
based Metabolic Syndrome In Men (METSIM) Study, with a special focus on insulin 
sensitivity and insulin secretion in these associations. Moreover, the determinants of 
glycated hemoglobin (HbA1c), the most commonly used marker of glycemia, were 
investigated. The results showed that tissue-specific markers of insulin resistance were 
superior to fasting plasma insulin levels in predicting the worsening of glycemia. Liver 
insulin resistance index was the best predictor for incident type 2 diabetes and 
cardiovascular events. With respect to the markers of dyslipidemia, the apolipoprotein 
A1/HDL cholesterol and apolipoprotein B/LDL cholesterol ratios were the strongest 
predictors for the worsening of glycemia and incident type 2 diabetes. The association of 
markers of dyslipidemia with insulin sensitivity was stronger than that with insulin 
secretion. HbA1c levels were mostly determined by non-glycemic factors, and only weakly 
by impaired insulin sensitivity and insulin secretion. In conclusion, the study identified 
several markers, which accurately predicted the worsening of glycemia, and the risk of type 
2 diabetes and cardiovascular events. 
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TIIVISTELMÄ 
 
Tyypin 2 diabeteksen esiintyvyys on lisääntynyt merkittävästi viime vuosikymmeninä.  
Tällä hetkellä tyypin 2 diabetesta sairastaa noin 9% maailman aikuisväestöstä. 
Insuliiniresistenssi (IR) ja heikentynyt insuliinin eritys ovat tärkeimmät 
aineenvaihduntahäiriöt tyypin 2 diabeteksessa. Diabeteksen ehkäisyssä on tärkeää 
tunnistaa korkeassa riskissä olevat henkilöt. Tutkimuksen päätavoite oli löytää uusia 
kudoskohtaisia (lihas, maksa, rasvakudos) insuliiniresistenssin mittausmenetelmiä ja 
lipidihäiriöihin liittyviä biomarkkereita, joilla voidaan ennustaa hyperglykemian 
kehittymistä sekä tyypin 2 diabeteksen ja sydän- ja verisuonisairauksien riskiä.  Lisäksi 
selvitettiin, mitkä tekijät liittyvät HbA1c-tasoon, joka on hyperglykemian seurannan tärkein 
mittari. Tutkimus osoitti, että insuliiniresistenssi lihaskudoksessa, maksassa sekä 
rasvakudoksessa ennusti hyperglykemian kehittymistä, tyypin 2 diabetekseen 
sairastumisen riskiä ja sydäntapahtumia. Maksan insuliiniresistenssiä kuvaava indeksi 
ennusti parhaiten tyypin 2 diabeteksen ja sydänsairauksien riskiä. Apolipoproteiini 
A1/HDL-kolesteroli -suhde ja apolipoproteiini B/LDL-kolesteroli –suhde ennustivat  
hyperglykemian kehittymistä ja tyypin 2 diabeteksen riskiä paremmin kuin yksittäiset 
lipoproteiinien tai apolipoproteiinien mittaukset. Lipoproteiinien ja apolipoproteiinien sekä 
niiden suhteiden yhteys insuliiniherkkyyteen oli vahvempi kuin yhteys insuliinin 
eritykseen. HbA1c-tasoa selittivät parhaiten hyperglykemiaan liittymättömät tekijät 
henkilöillä, joilla ei ollut diabetesta. Yhteenvetona voidaan todeta, että tutkimuksessa 
löydettiin useita uusia insuliiniresistenssin mittausmenetelmiä ja biomarkkereita, jotka 
ennustivat hyperglykemian etenemistä, tyypin 2 diabetesta ja sydänsairauksia.   
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 Abbreviations 
  
 
2hPG 2-hour plasma glucose during an 
OGTT  
Acyl-CoA Acyl coenzyme A 
ADA American Diabetes Association 
ADP                Adenosine diphosphate 
AGEs               Advanced glycation end products 
AIR Acute insulin secretory response  
Akt Protein kinase B 
ALT  Alanine aminotransferase  
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FFAs Free fatty acids 
FIN-D2D Finnish national diabetes  
 prevention program 
FPG Fasting plasma glucose  
FSIVGTT Frequently sampled intravenous 
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GLUT   Glucose transporter 
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HbA1c Glycated hemoglobin 
HDL  High density lipoprotein 
HEC Hyperinsulinemic euglycemic 
glucose clamp 
HOMA-B Homeostasis model assessment of 
insulin secretion 
HRs  Hazard ratios 
hs-CRP High-sensitivity C-reactive protein 
ICAM-1 Intracellular adhesion molecule 1 
IDL Intermediate density lipoprotein 
IFG  Impaired fasting glucose 
IIFG Isolated impaired fasting glucose 
IGT  Impaired glucose tolerance 
IIGT  Isolated impaired glucose tolerance 
IL-6  Interleukin 6 
IL1-RA  Interleukin 1 receptor antagonist 
IR  Insulin resistance 
IRAS Insulin Resistance Atherosclerosis 
Study 
IRS Insulin receptor substrate 
ISI Insulin sensitivity index 
Kg Kilogram 
LDL Low density lipoprotein 
MAPK Mitogen-activated protein kinase  
METSIM Metabolic Syndrom in Men Study 
NF-κB Nuclear factor kappa B  
NO Nitric oxid 
OGTT Oral glucose tolerance test  
OR Odds ratio 
PAI-1 Plasminogen activator inhibitor 1 
PDE3B Phosphodiesterase 3B 
XVIII 
 
PDK1 3-phosphoinositide-dependent 
protein kinase 1 
PI3K Phosphatidylinositol 3-kinase 
PKA Protein kinase A 
PKC Protein kinase C 
RAGE  The receptor for advanced glycation 
endproducts 
ROS Reactive oxygen species 
SD  Standard deviation 
SE  Standard error 
SG Glucose effectiveness index 
SGLT Sodium-glucose co-transporter 
s-HDL  Small high-density lipoprotein 
particle 
SI Insulin sensitivity index 
sd-LDL Small dense low-density lipoprotein   
particle 
T2D Type 2 diabetes 
TGs Triglycerides 
VCAM-1 Vascular cell adhesion protein 1 
VLDL Very-low-density lipoprotein 
vWF  von Willebrand factor 
 
 
 
 1 Introduction  
Type 2 diabetes is a chronic state of hyperglycemia. The prevalence and incidence of type 2 
diabetes are rapidly increasing worldwide. The number of people with diabetes will 
increase from 382 million (8.3% world´s adult population) in 2013 to 592 million in less than 
25 years, and more than 175 million people are unaware that they have diabetes (1). 
Prolonged exposure to hyperglycemia induces a large variety of alterations in various 
tissues that lead to micro- and macrovascular complications in type 2 diabetes.  
 
Insulin resistance (IR) in several tissues is the earliest detectable abnormality in the natural 
history of diabetes, and is frequently clustered with other cardiovascular risk factors, such 
as dyslipidemia, hypertension, endothelial dysfunction, low-grade inflammation and a 
prothrombotic state (2-4). IR increases the risk of cardiovascular disease (CVD) events, the 
leading cause of death in patients with type 2 diabetes (1). Lifestyle changes (5), which 
primarily increase insulin sensitivity, and pharmacological interventions (6) can reduce the 
incidence of type 2 diabetes and cardiovascular complications. Therefore, the identification 
of early markers for the development of type 2 diabetes is of great importance.  
 
IR is an important predictor of type 2 diabetes (7) and CVD events (8). Since IR affects 
several tissues, surrogate measures of tissue-specific IR might offer a new approach to 
evaluate their predictive power with respect to the deterioration of hyperglycemia, incident 
type 2 diabetes and CVD events. IR and hyperglycemia are closely related to disturbed 
lipid metabolism, including compositional changes of lipoprotein particles. Previous 
studies have suggested that an atherogenic lipid and apolipoprotein profile (elevated levels 
of plasma triglycerides (TGs), very-low density lipoprotein (VLDL) particles, post-prandial 
TG-rich lipoprotein remnants and apoliporotein B (ApoB) and low levels of high density 
lipoprotein (HDL) cholesterol) are associated with the future development of type 2 
diabetes in high-risk individuals (9). Also lipoprotein ratios have been proposed as 
potential markers for the future risk of type 2 diabetes (10). However, the results have been 
inconsistent, and it is still not known what are the best lipoprotein and apolipoprotein 
markers predicting the progression to overt diabetes.  
 
Glycated hemoglobin (HbA1c) is a widely used biomarker for type 2 diabetes and 
hyperglycemia that is strongly associated with micro- and macrovascular complications of 
type 2 diabetes. However, discordances between HbA1c and glucose measurements in the 
diagnosis of type 2 diabetes, as well as substantial inter-individual variation in HbA1c are 
frequently observed (11). Furthermore, the relationship of HbA1c with insulin secretion and 
insulin sensitivity, the two main pathophysiological disturbances in type 2 diabetes, is 
poorly understood.  
 
The aim of the present study was to identify new biomarkers and markers of tissue-specific 
IR that are useful for the prediction of glycemia, type 2 diabetes and CVD events. 
Additionally we investigated the glycemic and non-glycemic determinants of HbA1c.  
 
2 
 
2 Review of the Literature 
2.1 DEFINITION OF TYPE 2 DIABETES AND PRE-DIABETES  
Diabetes, including type 2 diabetes, is a metabolic disorder characterized by chronic 
hyperglycemia. The diagnosis is based on elevated fasting plasma glucose (FPG) levels 
(≥7.0 mmol/l) or elevated 2-hour plasma glucose (2hPG) levels (≥11.1 mmol/l) in an oral 
glucose tolerance test (OGTT) or elevated levels of glycated hemoglobin (HbA1c ≥6.5%) (12, 
13).  
 
Pre-diabetes is an intermediate state between normal glucose tolerance and diabetes, 
represented by moderately elevated fasting or postprandial glucose or HbA1c levels. The 
pre-diabetes state includes individuals with impaired fasting glucose (IFG), impaired 
glucose tolerance (IGT) or both (IFG+IGT) (14). Approximately 70% of individuals with pre-
diabetes develop type 2 diabetes, and the conversion to type 2 diabetes might take several 
years (5, 15). The pathophysiology of IFG and IGT is different. Subjects with IFG are 
characterized by impaired insulin secretion and hepatic IR, whereas subjects with IGT have 
more pronounced IR in peripheral insulin sensitive tissues (16). IFG and IGT are high-risk 
categories for the future development of type 2 diabetes (17, 18) and CVD events (19, 20). 
Table 1 shows the diagnostic criteria for diabetes and pre-diabetes based on American 
Diabetes Association (ADA) criteria (12).  
 
Table 1. Diagnostic criteria of pre-diabetes and diabetes according to the American Diabetes 
Association (ADA) (12).  
 
Stage FPG (mmol/l)  2hPG (mmol/l)  HbA1c (%) 
Normal <5.6  <7.8  <5.7 
Pre-diabetes     5.7-6.4 
    IIFG 5.6-6.9 and <7.8   
    IIGT <5.6 and 7.8-11.0   
    IFG+IGT 5.6-6.9 and 7.8-11.0   
Diabetes* ≥7.0 or ≥11.1 or ≥6.5 
 
FPG, fasting plasma glucose; 2hPG, 2-hour plasma glucose; HbA1c, glycated hemoglobin; IIFG, isolated 
impaired fasting glucose; IIGT, isolated impaired glucose tolerance in an OGTT. 
* The diagnosis should be based on two independent measurements on different occasions in the absence 
of symptoms of hyperglycemia (polyuria, polydipsia, weight loss, polyphagia, and blurred vision). 
2.2 PATHOPHYSIOLOGY OF PRE-DIABETES AND TYPE 2 DIABETES  
Euglycemia is maintained by a dynamic interaction between insulin secretion from 
pancreatic ß-cells and insulin action in insulin sensitive tissues. IR and impaired insulin 
secretion are the two major defects in type 2 diabetes, and can be detected already in subject 
with IFG and IGT (21). Type 2 diabetes develops when insulin secretion fails to compensate 
for prevailing IR in peripheral tissues. Development of type 2 diabetes is a gradual 
phenomenon with strong genetic and environmental influences (22).   
 
 
 
3 
 
2.2.1 Insulin secretion 
 
Insulin, the only blood-glucose lowering hormone, is released from the pancreatic ß-cells in 
a response to increased blood glucose levels. Glucose enters into the ß-cells through an 
insulin-independent process, mediated by plasma membrane-localized glucose transporters 
2 (GLUT-2). Glucose is phosphorylated by glucokinase upon entering the cell, and then 
metabolized to adenosine triphosphate (ATP), the central energy molecule, via several 
biochemical pathways (23). Elevated cytoplasmic ATP/ADP ratio initiates the closure of the 
ATP-sensitive potassium channel (K+ channel), which leads to depolarization of the ß-cell 
membrane. The membrane depolarization opens transmembrane voltage-dependent Ca2+ 
channels followed by Ca2+ influx. An increase in intracellular calcium concentrations 
triggers the exocytosis of insulin from vesicles. Released insulin then diffuses to pancreatic 
islets capillaries, and reaches its target tissues through the blood circulation (24) (Figure 1). 
 
 
 
Figure 1. Mechanisms of glucose-stimulated insulin secretion from the ß-cells (25).   
 
Insulin secretion from ß-cells is pulsatile with a biphasic pattern (26). The first (acute) phase 
culminates 5-6 minutes after the glucose stimulus, and involves the release of insulin 
already stored in the ß-cells. The second, a more sustained phase is characterized by 
gradual increase in insulin secretion and it lasts until hyperglycemia persists (27). In type 2 
diabetes a typical biphasic pattern is disrupted. Early stages of type 2 diabetes are 
characterized by significant reduction of the first-phase insulin secretion, which leads to 
postprandial hyperglycemia, whereas the second phase is enhanced (28). Further decline in 
the ß-cell function disturbs the second phase, and thus contributes to fasting 
hyperglycemia. In pre-diabetes both IFG and IGT are characterized by a reduction in early-
phase insulin secretion, and subjects with IGT have additionally impaired second phase of 
insulin secretion (15, 29). The reduction in both phases of insulin secretion in non-diabetic 
individuals is a strong marker of the subsequent development of diabetes (30-32). 
 
An increase in insulin release activates insulin biosynthesis (Figure 2). Insulin is 
synthesized as a single 110-amino acid precursor pre-proinsulin in the endoplasmic 
reticulum and processed to proinsulin by removal of the amino terminal signal sequence. 
Proinsulin consists from two chains A and B, linked by disulfide bonds and connected by 
C-peptide. In the Golgi apparatus proinsulin is packed into secretory vesicles, in which 
convertase 2 and 3 and carboxy peptidase H excise the C-peptide from proinsulin molecule 
and generate the mature form of insulin (33). After secretory stimulus the mature insulin 
and C-peptide are co-secreted in equimolar amounts, together with small amounts of 
uncleaved proinsulin and its intermediates (34). Proinsulin and its conversion 
intermediates have a longer half-life than insulin, and under the physiological conditions 
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plasma insulin levels include about 10-15% proinsulin and its intermediates. C-peptide is a 
useful marker of insulin secretion and allows to distinguish endogenous and exogenous 
sources of insulin. Increased plasma proinsulin levels and the ratios of proinsulin/insulin 
and proinsulin/C-peptide provide information about the efficacy of proinsulin processing, 
and are used as early markers of ß-cell dysfunction (35). Moreover, increased plasma 
proinsulin levels and the proinsulin/insulin ratio are associated with glucose intolerance, IR 
and the development of type 2 diabetes (36-39). 
 
Impaired insulin secretion is a key determinant for the progression to type 2 diabetes, and 
is found uniformly in all ethnic populations (7, 40). Impairment of ß-cell function starts 10-
12 years before the diagnosis of diabetes, and at the time of diagnosis of type 2 diabetes 
approximately 50% of ß-cell function is lost (41, 42). In individuals with pre-diabetes IR is a 
characteristic finding, and euglycemia is maintained by a compensatory increase in insulin 
secretion (compensatory hyperinsulinemia). In individuals with type 2 diabetes IR does not 
deteriorate when hyperglycemia develops, but insulin secretion continues to decrease (43). 
A substantial decrease in insulin secretion appears in the diabetic range of plasma glucose 
levels when ß-cells fail to compensate IR in peripheral tissues (44). 
 
 
 
Figure 2.  Biosynthesis of insulin. Modified from (45). 
 
Mechanisms underlying impaired insulin secretion are multifactorial. Twin studies and 
studies in the first-degree relatives of type 2 diabetic subjects have indicated a strong 
genetic basis of ß-cell dysfunction (46-50), and several gene variants have been associated 
with insulin secretion, including genes encoding for transcription factors, glucose 
metabolism proteins, molecules of the insulin signaling pathways, and others (51-54). 
Chronic hyperglycemia (glucotoxicity) and accumulation of excess lipids in non-adipose 
tissues (lipotoxicity) have been strongly associated with reduced ß-cell function and mass. 
Glucotoxicity increases apoptosis of ß-cells and in vitro impairs gene transcription, which 
leads to a decrease in insulin synthesis and secretion from ß-cells. Fluctuations in the levels 
of free fatty acids (FFAs) are necessary for normal ß-cell function. However, chronic 
exposure to high FFA levels leads to ß-cell injury, inhibition of insulin gene expression and 
increased ceramide production, resulting in impaired insulin secretion (55, 56). 
Furthermore, aging, physical inactivity and obesity accelerate the impairment in ß-cell 
function (57). 
 
                                                                                                                         
5 
 
2.2.2 Insulin resistance 
 
IR is characterized by decreased rates of insulin-mediated glucose uptake by insulin-
sensitive target tissues (liver, skeletal muscle, and adipose tissue). IR is an early event in the 
development of type 2 diabetes, and precedes an increase in glucose levels attributable to 
decreased insulin secretion (58).  
 
Normal insulin action is initiated through the binding and activation of insulin receptors in 
its target tissues, which consequently stimulate glucose uptake into the cells. The insulin 
receptor has intrinsic tyrosine kinase activity, and consists of two extracellular α-subunits 
and two transmembrane ß-subunits linked by disulphide bonds. Insulin binds to the 
extracellular α-subunit and triggers conformational change of ß-subunit, which enables 
ATP to bind to the intracellular part of ß-subunit. Binding of ATP results in the 
phosphorylation of ß-subunit conferring tyrosine kinase activity (59). The activated insulin 
receptor subsequently phosphorylates intracellular substrate proteins known as insulin 
responsive substrates (IRS; IRS 1-6), and phosphorylated IRS then activates the two main 
signaling cascades. The first, the phosphatidylinositol 3-kinase (PI3K) pathway, is 
responsible for the majority of metabolic actions of insulin (glucose, lipid and protein 
metabolism), and the second, mitogen-activated protein kinase (MAPK) pathway, controls 
mitogenesis, cell growth and differentiation. PI3K activates 3-phosphoinositide-dependent 
protein kinase 1 (PDK1). PDK1 subsequently activates Akt, activated Akt induces the 
translocation of glucose transporters from their intracellular pool to the plasma membrane 
resulting in the uptake of glucose into the cell. PI3K also promotes proteins, glycogen, lipid 
and protein synthesis, anti-lipolysis, and controls hepatic gluconeogenesis (60, 61) (Figure 
3).  
 
Several genetic and environmental factors have been implicated in altering the insulin 
signaling pathway. A minority of insulin resistant cases are characterized by a single 
genetic or acquired trait (62). At the molecular level, impairment in insulin action involves 
inactivation of insulin during its circulation, defects at the receptor and postreceptor levels, 
and tissue-specific alterations. Impaired tyrosine phosphorylation of IRS-1 and PI3K 
activation has been associated with IR in animal models, individuals with type 2 diabetes, 
and in 30% of subjects at high risk for type 2 diabetes (63). Another potential mechanism 
which may lead to IR is reduced expression of PI3K, which has been described in skeletal 
muscle in non-obese and obese individuals (64-66). In addition to the defects in the insulin 
signaling pathway, environmental factors such as visceral obesity, physical inactivity and 
smoking have a strong negative impact on insulin sensitivity. 
 
 
 
Figure 3. Insulin signaling pathway. Adapted from (33, 66, 67). 
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2.3 TISSUE-SPECIFIC INSULIN RESISTANCE  
The effects of insulin vary according to the physiological function of the tissues. Insulin’s 
main target tissues with respect to glucose metabolism are muscle, liver and adipose tissue. 
In addition, there are many other important targets of insulin, including ß-cells, brain, 
endothelium, and heart, that maintain metabolic and cardiovascular homeostasis.  
 
In the fasting state the majority of glucose is utilized in insulin-independent tissues, such as 
brain (~50%) and splanchnic organs (~25%), whereas insulin-dependent tissues, mainly 
skeletal muscle and less liver and adipose tissue are responsible for remaining 25% of 
glucose utilization (44). In the fasting state glucose homeostasis and the degree of 
hyperglycemia are primarily determined by endogenous glucose production by the liver 
(responsible for ~80% of endogenous glucose production), and ~20% of glucose production 
is derived from the kidneys (68). In the postprandial state insulin promotes glucose uptake 
into insulin-sensitive tissues, mostly skeletal muscle (accounts for ~60% of glucose uptake), 
liver (~30% of glucose uptake), and adipose tissue (~10% of glucose uptake) (69). Glucose is 
primarily stored as glycogen, mainly in the liver (~10% of the liver's weight) and skeletal 
muscle (~1% of its weight) (70). 
 
IR is frequently present simultaneously in several tissues (Figure 4), but it may affect only 
one tissue and the severity may differ across the tissues. Subjects with isolated IFG have 
hepatic IR and almost normal skeletal muscle insulin sensitivity, whereas subjects with IGT 
have a more pronounced defect in skeletal muscle insulin sensitivity (71). 
 
 
 
Figure 4. Insulin resistance in different tissues in type 2 diabetes (72, 73). 
2.3.1 Skeletal muscle 
 
IR in skeletal muscle is defined as impaired glucose disposal resulting in postprandial 
hyperglycemia (74). In healthy individuals approximately 80% of glucose is taken up by 
skeletal muscle under euglycemic hyperinsulinemic conditions and stored as glycogen via 
activation of glycogen synthase, and the remaining 20% of glucose is oxidized to CO2 and 
H2O by pyruvate dehydrogenase enzyme complex (69, 74).  
 
In the insulin resistant state, glucose uptake and glycogen synthesis in skeletal muscle are 
markedly reduced (44,75), especially in individuals with type 2 diabetes (76). Skeletal 
muscle IR is mainly attributable to alterations in the insulin-signaling pathways. Alterations 
might appear at the level of: 1) insulin signaling (reduced insulin receptor tyrosine 
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phosphorylation, decreased IRS-1 tyrosine phosphorylation, and decreased PI3K 
activation); 2) glucose transport (a defect in translocation of GLUT-4); and 3) glucose 
metabolism (decreased glucose phosphorylation, decreased glucose oxidation and defect in 
the activation of glycogen synthase) (64, 77-79). Several studies have consistently shown 
reduced IRS-1 phosphorylation, lowered PI3K activity, and Akt activation in the skeletal 
muscle of individuals having type 2 diabetes (80, 81).  
2.3.2 Liver 
 
Liver is a key insulin sensitive organ that maintains whole body glucose homeostasis. 
Under insulin sensitive conditions and in the fasting state, the liver provides necessary 
glucose for the brain by glycogenolysis and gluconeogenesis, whereas in the postprandial 
state, insulin secreted from ß-cells suppresses liver glucose production by inhibiting 
glycogenolysis and gluconeogenesis (82). Hepatic IR is characterized by enhanced 
gluconeogenesis in the fasting state, and reduced suppression of hepatic glucose 
production in response to insulin in the postprandial state (83, 84). Increased rate of hepatic 
glucose production is responsible for fasting and postprandial hyperglycemia. In insulin 
resistant states the expression of two main gluconeogenic enzymes (phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase) is increased, whereas expression of enzymes 
regulating glycogen synthesis and glycogenolysis is decreased (82, 85, 86). Furthermore, 
defects in the IRS-1 and IRS-2 insulin receptor substrate signaling pathways contribute to 
hyperglycemia and hepatic IR (87).  
2.3.3 Kidneys 
 
The kidneys are involved in the regulation of glucose homeostasis in type 2 diabetes via 
three mechanisms: 1) glucose release into the circulation via gluconeogenesis; 2) glucose 
uptake from the circulation for energy needs; and 3) glucose reabsorption into the 
circulation from glomerular filtrate, mediated by sodium glucose co-transporters (SGLTs) 
and glucose transporters (GLUT-2) (68).  
 
The renal cortex possesses all gluconeogenic enzymes and is responsible for 15-30% of 
endogenous glucose production in the postabsorptive state (88, 89). Insulin reduces renal 
gluconeogenesis directly by enzyme activation or deactivation. Insulin also decreases the 
availability of gluconeogenic substrates (lactate, glutamine, and glycerol), resulting in 
reduced glucose release into the circulation (68, 90). Excessive renal glucose release and 
increased renal gluconeogenic enzyme activity in the basal and postprandial states have 
been demonstrated in diabetic animals (91) and also in patients with type 2 diabetes (92). 
The increment in renal glucose release has been shown to be comparable with the increase 
in hepatic glucose release (92). Glucose utilization occurs predominantly in the renal 
medulla. The kidney accounts for ~10% of glucose removal from the circulation in the 
postabsorptive state, and ~10-15% in the postprandial state (68). In type 2 diabetes the renal 
glucose uptake is increased in both postabsorptive and postprandial states (92). Postpradial 
renal glucose uptake is raised more than two-fold in diabetic individuals than in non-
diabetic persons (93). The kidneys normally reabsorb 99% of filtered glucose and return it 
into the circulation, which is mediated by SGLTs (mainly SGLT-2) and GLUT-2 (68). The 
studies conducted in diabetic human and animal renal tubular cells have suggested that the 
expression of SGLT-2 and GLUT-2 is upregulated in diabetes (94-96), allowing more 
glucose re-enter the circulation. Thus, the kidneys contribute to hyperglycemia in type 2 
diabetes by increased gluconeogenesis and renal glucose uptake and by enhanced glucose 
reabsorption. 
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2.3.4 Adipose tissue  
 
A major function of white adipose tissue is the storage of FFAs as triglycerides (TGs) to 
provide a source of energy in the body. Insulin stimulates glucose uptake into adipocytes 
and inhibits lipolysis and release of FFAs from them by suppressing hormone-sensitive 
lipoprotein lipase. IR in adipose tissue is manifested as the inability of insulin to suppress 
lipolysis, which leads to increased intracellular hydrolysis of TGs and excessive secretion of 
FFAs into the circulation (97, 98). Thus, the basal rate of lipolysis is increased despite a high 
plasma insulin concentration. Elevated levels of FFAs adversely affect the insulin signaling 
pathway and disrupt insulin-stimulated glucose uptake in skeletal muscle, stimulate liver 
gluconeogenesis and impair insulin secretion in pancreatic ß-cells. Chronically elevated 
levels of FFAs contribute to increased deposition of TGs in non-adipose tissues (muscle, 
liver, pancreas), which closely correlates with IR in these tissues. A large number of studies 
have confirmed that intracellular metabolites of TGs and FFAs (fatty acyl-CoA, 
diacylglycerol, and ceramides) in non-adipose tissues further deteriorate insulin sensitivity 
(lipotoxicity) (99-101). In addition, high levels of FFAs stimulate hepatic production of very-
low density lipoprotein (VLDL) particles by activating sterol regulatory element-binding 
protein 1 and by impairing VLDL clearance, which further worsens hyperglycemia and 
leads to atherogenic dyslipidemia (102).  
 
IR in adipose tissue is observed long before disturbances in glucose tolerance develop (66). 
Decreased expression of GLUT-4 and IRS-1 proteins in adipocytes is an early cellular 
marker of adipose-tissue IR (103, 104). Insulin has a potent antilipolytic effect in adipose 
tissue. It stimulates the uptake of circulating TGs into the adipose tissue by enhancing 
lipoprotein lipase activity while simultaneously exerting antilipolytic effects through the 
inhibition of hormone-sensitive lipases. Insulin inhibits lipolysis by phosphorylation and 
activation of phosphodiesterase 3B (PDE3B), which hydrolyzes cyclic adenosine 
monophosphate (cAMP) to adenosine monophosphate (AMP). The activation of PDE3B 
decreases intracellular cAMP, which in turn reduces cAMP-dependent protein kinase A 
(PKA) activity. The reduction of PKA activity decreases the hydrolysis of TGs, and thus 
suppresses release of FFAs from adipocytes (105). Most individuals with type 2 diabetes are 
obese and have fat accumulated in visceral organs. Adipocytes of obese individuals are 
hypertrophic, and their capacity to store TGs is disturbed. Visceral fat is more resistant to 
antilipolytic effects of insulin than non-splanchnic fat, and releases large amounts of FFAs 
(106) which exacerbates systematic IR. Moreover, adipose tissue of obese individuals 
contains an increased number of macrophages compared to non-obese individuals (107). 
Hypertrophic adipocytes and adipose tissue-resident immune cells (lymphocytes and 
macrophages) overexpress proinflammatory cytokines and adipokines (TNFα, IL-6, 
angiotensin, plasminogen activator inhibitor-1 (108), leptin, retinol-binding protein, 
resistin), which negatively modulate insulin sensitivity, and downregulate insulin-
sensitizing adiponectin (109-111). Metabolic effects of insulin in the liver, adipocytes and 
muscle cells are shown in Figure 5. 
2.3.5 Other tissues 
 
Pancreas  
 
IR in pancreatic β-cells might contribute to the pathogenesis of type 2 diabetes. The 
importance of insulin signaling in pancreatic β-cells was first demonstrated in IRS-2 
deficient mice (112). Mice lacking insulin receptors in β-cells also have a defect in glucose 
sensing and a reduced pancreatic β-cell mass (113, 114).  
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Overconsumption of saturated fat is strongly associated with IR and ß-cell dysfunction, 
since it desensitizes glucose recipient tissues to the action of insulin. High saturated fats, 
derived mainly from the diet or from lipolysis of fat depots, lead to competition of FFAs 
and glucose for uptake and metabolism in the tissues. Persistent hyperglycemia and 
increased saturated FFA levels induce a glucolipotoxic state by increasing oxidative stress, 
subsequently reducing insulin synthesis and secretion, and thus compromising both ß-cell 
structure and function (115-118).  
 
Brain  
 
The central effects of insulin are primarily catabolic (i.e. reducing food intake and body 
weight), whereas peripheral effects of insulin are anabolic (increasing energy storage) (119). 
Insulin action in the hypothalamus is essential in the regulation of energy homeostasis and 
feeding. Moreover, insulin suppresses hepatic glucose production also by its action in 
hypothalamus, which is mediated by the vagal nerve. The glucose-sensing neurons present 
particularly in the ventromedial hypothalamus (VMH), and in the lateral hypothalamus 
(LH) are also involved in the regulation of glucose metabolism (120). The stimulation of 
VMH, the presumed sympathetic center, causes activation of the key glycogenolytic 
enzyme (glycogen phosphorylase), which results in hyperglycemia and marked reduction 
in the liver glycogen content. By contrast, stimulation of LH, which is associated with 
parasympathetic facilitation, leads to hepatic glycogenesis through the activation of 
glycogen syntethase (121). Both diabetes and obesity are associated with several alterations 
in brain glucose sensing (122). The main feature of IR in the brain is a dysfunction of the 
neuronal insulin receptor signaling, demonstrated mostly by defects in the PI3K pathway 
that is similar to defects in the insulin signaling pathways in the peripheral tissues. Brain IR 
is manifested as altered feeding behavior and increased hepatic glucose production (123-
125). 
 
 
 
Figure 5. Metabolic effects of insulin in the liver, adipocytes and muscle cells. Green arrows 
indicate the direction of processes facilitated by insulin. Red arrows indicate the direction in the 
absence of insulin. Black arrows show non-insulin dependent processes. The lipoprotein lipase is 
located in the membranes of the adipocytes capillaries (126). 
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2.4 INSULIN RESISTANCE AND CARDIOVASCULAR DISEASE 
CVD is the leading cause of mortality among people with type 2 diabetes, accounting for 
more than 50% of all deaths (1). Subjects with IFG or IGT have a two-fold and subjects with 
type 2 diabetes a two- to three-fold increased CVD mortality compared to individuals with 
normoglycemia (19, 127). Meta-analysis of 102 prospective studies has shown that type 2 
diabetes confers about a two-fold excess risk of coronary heart disease, major stroke 
subtypes, and deaths from other vascular causes (128). Moreover, individuals with type 2 
diabetes and a clinical CVD event have worse prognosis than non-diabetic individuals who 
have a CVD event (129, 130).  
 
Type 2 diabetes and pre-diabetes frequently cluster with several classic CVD risk factors, 
including obesity, hypertension and atherogenic dyslipidemia. IR in several tissues is the 
main mechanism linking type 2 diabetes, pre-diabetes, and CVD risk factors, and it is 
clearly involved in the pathogenesis of CVD. IR has been shown to be a strong risk factor 
for coronary heart disease (131, 132), asymptomatic atherosclerosis (133), and CVD (8). 
Furthermore, hyperinsulinemia, a marker of IR, has been associated with CVD events in 
non-diabetic individuals, independently of other risk factors (131, 134). IR as a CVD risk 
factor accelerates atherogenesis either directly through adverse effects on the endothelium 
and downregulation of the insulin signaling pathway, and indirectly through changes in 
CVD risk factors (43).  
2.4.1 Insulin resistance and atherosclerosis 
 
A large body of evidence supports an important role of IR in the atherogenic process (131, 
133, 135). The lack of appropriate insulin signaling can promote both atherogenesis and 
advanced plaque progression by mechanisms involving systemic factors such as 
dyslipidemia, hypertension and a proinflammatory state, and by mechanisms of disturbed 
insulin signaling at the level of the intimal cells that participate in atherosclerosis, including 
endothelial cells, vascular smooth muscle cells and macrophages (Figure 6). 
 
 
 
 
Figure 6. Association of insulin resistance with cardiovascular risk factors and atherosclerosis 
(136).  
 
Endothelial cells insulin resistance 
 
Impairment in endothelial function is the earliest finding in the pathogenesis of 
atherosclerosis, and is closely associated with IR (43). Knockout of the endothelial insulin 
receptor in apoliporotein E-null mice causes a two- to three-fold increase in the size of 
atherosclerosis lesions (137). Under the physiological conditions, insulin stimulates blood 
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flow, capillary recruitment and endothelial nitric oxid (NO) synthesis and release. 
Endothelial IR manifests itself as reduced blood flow, mainly attributable to decreased 
insulin-mediated NO production. Reduced blood flow limits the delivery of insulin into the 
target tissues, and thus reduces glucose uptake by these tissues. Furthermore, down-
regulation of the insulin receptor Akt1 pathway induces an increase in the levels of 
adhesion molecules ICAM-1 and VCAM-1 (43). 
 
Macrophage insulin resistance 
 
Macrophages are involved in both early and advanced stages of atherosclerotic process. 
Loss of insulin action in macrophages contributes to the formation of necrotic core in 
atherosclerotic plaque by enhanced macrophage apoptosis (138). Pro-apoptotic pathways in 
macrophages are activated due to long-term endoplasmic reticulum stress and activation of 
the unfolded protein response (139). The necrotic core of atherosclerotic plaque is more 
prone to rupture and can precipitate to thrombosis or lead to unstable angina pectoris, 
myocardial infarction, or stroke (140). However, IR in macrophages has been shown to have 
only a modest effect on atherosclerotic lesion growth (141). 
 
Insulin resistance and blood pressure 
 
Hypertension is a well-established risk factor for CVD. Approximately 50% of individuals 
with hypertension are insulin resistant (2), and about two thirds of individuals with type 2 
diabetes have elevated blood pressure (142). Several pathophysiological mechanisms 
explaining association between IR and hypertension have been proposed. Insulin is 
involved in the regulation of sympathetic nerve activity, and hyperinsulinemia present in 
the insulin resistant state increases sympathetic nervous system activity, and thus 
contributes to hypertension (143). In addition, other effects of IR, including decreased NO 
production, renal sodium retention, activation of renin-angiotensin-aldosteron system and 
proliferation of smooth muscle cells are potential mechanisms explaining increased blood 
pressure in individuals with type 2 diabetes (43, 142). 
 
Insulin resistance and clotting  
 
The excess risk of CVD events in IR is also mediated by enhanced secretion of coagulation 
factors and impaired fibrinolysis. Increased plasma concentrations of fibrinogen, factor VII 
(FVII) and von Willebrand factor (vWF, marker of endothelial damage and dysfunction) 
and suppression of fibrinolysis due to high plasma concentrations of plasminogen activator 
inhibitor (PAI-1) have been related to the development of CVD (144, 145). The cause for 
increased levels of fibrinogen in the insulin resistant state is unclear, but it may be triggered 
by obesity (2). Factor VII has been shown to be increased during postprandial 
hyperlipidemia (146), suggesting increased risk for acute CVD events. PAI-I has been 
associated with premature CVD (147). Increased expression and secretion of PAI-I by 
hepatocytes and endothelial cells is induced by increased levels of insulin, proinsulin-like 
molecules, TG-rich lipoproteins and oxidized LDL (148). Moreover, suppressed NO 
production and prostacyclin synthesis result in platelet aggregation (149). 
 
IR is associated with plasma lipid and lipoprotein abnormalities, including reduced levels 
of high-density lipoprotein cholesterol (HDL cholesterol), a predominance of atherogenic 
small dense LDL particles (sd-LDL), small HDL (s-HDL) particles, and elevated levels of 
total TGs (150). Additionally, IR has significant effects on lipoprotein size and subclass 
particle concentrations of VLDL, LDL, and HDL (151, 152). Dyslipidemia in IR is driven by 
increased influx of FFAs from adipose tissue into the liver, which promotes hepatic 
overproduction of VLDL particles resulting in a higher number of atherogenic VLDL 
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remnants, and simultaneously increased synthesis of apolipoprotein B (ApoB). A low HDL 
cholesterol level is frequently seen in individuals with IR. The following two mechanisms 
lower HDL cholesterol level: 1) cholesterol ester transfer protein mediates the transfer of 
cholesterol from HDL to the lipoproteins containing apoB; and 2) hepatic and endothelial 
lipases are upregulated in the insulin-resistant state and stimulate catabolism of HDL (150). 
Low concentrations of HDL cholesterol and apolipoprotein A1 (ApoA1) promote the 
accumulation of cholesterol into blood vessel wall and thereby contribute to atherosclerosis 
(153). 
 
Insulin resistance and hyperglycemia  
 
Hyperglycemia is a direct consequence of IR. Prolonged hyperglycemia has major effects on 
the pathogenesis of atherosclerosis, and several mechanisms which contribute to increased 
risk of CVD events are shared by IR and hyperglycemia (43). Excess risk of CVD events 
starts at levels of glycemia that are lower than the threshold for the diagnosis of diabetes 
(154). However, the effects of hyperglycemia alone on the risk of CVD are difficult to 
evaluate because IR is present several years before hyperglycemia develops. Thus, changes 
in cardiovascular risk factors occur already in the context of IR, and both IR and 
hyperglycemia are responsible for the increased risk of CVD events (43). 
 
Hyperglycemia induces a large number of alterations in vascular tissue that accelerate 
atherosclerosis. The key mechanisms responsible for increased risk of CVD events are: 1) 
non-enzymatic glycosylation of proteins and lipoproteins in the arterial wall; 2) oxidative 
stress (disturbance in the balance between the production of reactive oxygen species (ROS) 
and antioxidants); and 3) activation of major signal transduction pathways inducing 
vascular damage (155-157). Hyperglycemia induces the overproduction of ROS, which 
promotes the formation of advanced glycation end products (AGEs), and activates several 
signal transduction pathways including polyol and hexosamine pathways, PKC pathway 
and NF-κB pathway. AGEs have been implicated in microvascular and macrovascular 
complications of type 2 diabetes and are among the major pro-oxidant, cytotoxic 
compounds that contribute to chronic inflammation (158). Vascular damage associated with 
AGEs is related to excess production of free radicals and reduced NO production. The 
AGEs also induce excessive cross-linking of collagen and other extracellular matrix proteins 
that lead to the accumulation of LDL particles (159). LDL particles have prolonged half-life, 
which contribute to oxidation of LDL particles, and thus facilitate their entry into the 
arterial wall.  
 
In addition, the principal receptor for AGEs, which exists as a trans-membrane signalling 
receptor (105), and as a circulating form, soluble RAGE (sRAGE) may be important for 
initializing and maintaining the pathological processes that result in various entities of 
CVD disease (160, 161). Increased expression of RAGE has been found in activated 
endothelial cells, vascular smooth muscle cells and proinflammatory cytokines in 
atherosclerotic plaques. The interaction of RAGE with RAGE ligands further increases the 
secretion of proinflammatory cytokines and cell adhesion molecules (162). RAGE may have 
a significant role in leukocyte recruitment into the intima of atherosclerotic lesions that 
results in amplification of vascular inflammation and oxidative stress (163, 164).  By 
contrast, sRAGE competitively inhibits the binding of RAGE ligands to RAGE and thus 
attenuates the development of atheroscleroctic plaques in vivo (161).  
 
The PKC pathway mediates changes in endothelial cells, including permeability, 
inflammation, angiogenesis, cell growth, and apoptosis (165). Activation of the NF-κB 
pathway leads to expression of several inflammatory genes, including adhesion molecules 
that facilitate monocyte adhesion to endothelial cells. Monocytes accumulate in the arterial 
13 
 
wall and differentiate into intimal macrophages, which take up lipids and become foam 
cells, resulting in accelerated atherosclerotic plaque formation (7, 157, 166). 
 
2.5 PREDICTORS AND BIOMARKERS FOR TYPE 2 DIABETES, GLYCEMIA 
AND CARDIOVASCULAR EVENTS  
The prevalence and incidence of type 2 diabetes are rapidly increasing worldwide. 
Therefore, the identification of early predictors, including markers of IR and secretion, for 
type 2 diabetes is of a great importance to plan intervention programs in people at high risk 
of diabetes.  
2.5.1 Markers of insulin sensitivity and insulin secretion 
 
Both impaired insulin sensitivity and pancreatic ß-cell dysfunction are strong predictors of 
the worsening of glycemia, type 2 diabetes and CVD events (7, 8, 167, 168). Methods 
assessing insulin sensitivity and insulin secretion can be divided into three main categories 
1) direct methods; 2) indirect methods; and 3) surrogate markers of IR and insulin secretion. 
 
2.5.1.1 Direct measures of insulin sensitivity and insulin secretion  
 
The euglycemic hyperinsulinemic clamp and hyperglycemic clamp provide quantitative 
measures of insulin sensitivity and insulin secretion, respectively. Glucose clamp methods 
are considered “gold standards” for measuring insulin sensitivity and insulin secretion 
(169). However, clamp studies are costly and labor intensive, and therefore they are not 
suitable for large epidemiological studies. 
 
Euglycemic hyperinsulinemic glucose clamp 
 
The euglycemic hyperinsulinemic clamp is the reference method for quantifying insulin 
sensitivity in vivo. It measures glucose utilization and glucose production rates during the 
steady state of hyperinsulinemia (169). Incorporation of radioactive-labeled glucose during 
the euglycemic hyperinsulinemic clamp allows assessment of tissue-specific insulin 
sensitivity (170). This technique requires a steady intravenous insulin infusion 
administrated in one arm, and serum glucose level is “clamped” at the fasting level by 
administering a variable intravenous glucose infusion into the other arm. The infused 
insulin suppresses hepatic glucose production. Skeletal muscle is the major tissue of 
glucose disposal (80-90%), and therefore the euglycemic hyperinsulinemic clamp reflects 
mainly skeletal muscle glucose uptake (Figure 7). Once a steady state is reached (usually 
during 30-60 min of the test) the rate of glucose infusion equals the rate of peripheral 
glucose disposal rate. Insulin sensitivity is quantified as the glucose infusion rate during the 
clamp (M value). Highly insulin resistant individuals require minimal exogenous glucose, 
whereas insulin sensitive individuals require a considerable amount of exogenous glucose 
to maintain euglycemia. The euglycemic hyperinsulinemic clamp allows the measurement 
of a dose-response curve to insulin action if varying insulin concentrations are used (171). 
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Figure 7. Reduced glucose uptake by muscle during the euglycemic hyperinsulinemic clamp in 
patients with type 2 diabetes. Modified from (58).  
 
Hyperglycemic clamp 
  
The hyperglycemic clamp provides estimates of both the first-phase and second-phase 
insulin response after an intravenous bolus dose of glucose, followed by a constant infusion 
of glucose to achieve target glucose level (169). Hyperglycemia stimulates biphasic insulin 
secretion and glucose disposal. The insulin area under the curve (AUC) during the first ten 
minutes reflects the first phase insulin response and the AUC during the later period 
reflects the late insulin response. Impairment in the first phase of insulin secretion is a very 
sensitive marker of early ß-cell dysfunction and is predictive of future type 2 diabetes (172, 
173). 
 
2.5.1.2 Indirect measures of insulin sensitivity and insulin secretion  
 
Frequently sampled intravenous glucose tolerance test  
 
While the euglycemic clamp method measures the effect of insulin on glucose uptake at 
steady state, the frequently sampled intravenous glucose tolerance test (FSIVGTT) and the 
minimal model developed by Dr. Richard Bergman uses the dynamic relationship between 
glucose and insulin (174). It provides reliable markers for both insulin sensitivity and 
insulin secretion based on glucose and insulin measurements obtained during a frequently 
sampled intravenous glucose tolerance test. The minimal model allows the calculation of 
two indices: SI (insulin sensitivity index) and SG (glucose effectiveness index). SI provides 
information about peripheral and liver insulin sensitivity and, the ability of insulin to 
enhance glucose uptake and to inhibit hepatic glucose production, whereas SG represents 
the effect of glucose on its own disappearance independently of insulin. In addition, the 
minimal model estimates the acute insulin response (AIR), and the Disposition index (DI). 
The AIR to glucose, an index of first-phase insulin secretion, is calculated as the mean 
incremental increase in plasma insulin concentration in samples obtained at 3, 4, 5 and 10 
min after the glucose bolus (175, 176). A decreased AIR has been associated with high risk 
of developing diabetes in prospective population-based studies (7, 177, 178).  
 
Oral glucose tolerance test  
 
The oral glucose tolerance test (OGTT) is easy to perform and commonly used in the 
clinical setting to detect glucose intolerance and type 2 diabetes (12). It reflects the normal 
physiology of glucose and insulin flux, is less costly and non-invasive, and therefore more 
suitable for large population-based studies (71). Plasma glucose and insulin responses 
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during an OGTT reflect insulin secretion capacity and tissue sensitivity to insulin. 
Therefore, an OGTT is most frequently used in the evaluation of insulin sensitivity and 
insulin secretion. Although an OGTT provides information about the efficiency of 
peripheral tissues to utilize glucose after a glucose load, it cannot be used to assess tissue-
specific insulin sensitivity.  
 
After an overnight fast, blood glucose and insulin levels are determined after a glucose load 
(75 g of glucose) at different time points (179). Fasting plasma insulin concentrations are 
frequently used as index of IR, and the ratio of insulin to glucose 30 minutes after the 
administration of oral glucose load (the insulinogenic index) has been used as a surrogate 
marker of insulin secretion. The insulinogenic index has been shown to predict future 
development of type 2 diabetes in several epidemiological studies (180-182). The AUC for 
glucose and insulin during an OGTT integrates the entire blood glucose and insulin 
response over time and gives valuable information on the future risk of diabetes. However, 
its value is limited due to the large intra-individual variation in glucose and insulin levels, 
day-to-day variability in gastrointestinal function and poor reproducibility (183, 184). 
Estimation of insulin secretion obtained in an OGTT may be biased by increased hepatic 
first-pass insulin extraction. Accordingly, single or integrated measures of insulin 
concentrations in an OGTT may not reflect actual insulin secretion. Insulin secretion indices 
based on the ratio of insulin to glucose at 30 min after glucose ingestion could be influenced 
by a delayed but not absolutely defective insulin secretion. Oral glucose administration 
induces a greater insulin increment than intravenous glucose administration, which is 
attributable to the incretin effect (185).  
 
2.5.1.3 Surrogate indices of insulin sensitivity and insulin secretion 
 
Surrogate indices of insulin sensitivity and secretion have been proposed and validated 
against the reference measurements to simplify determination of IR and insulin secretion in 
large epidemiological studies. The usefulness of surrogate indices of insulin sensitivity and 
secretion for epidemiological studies depends on the strength of their correlation with the 
reference measurements and their ability to predict type 2 diabetes in prospective analyses 
(182). Studies comparing surrogate and direct measurements have shown that surrogate 
indices of insulin sensitivity and insulin secretion correlate reasonably well with insulin 
sensitivity and insulin secretion measured by direct methods (182, 186, 187).  
 
Surrogate indices of insulin sensitivity and secretion can be calculated based on fasting 
insulin and glucose levels (fasting sample indices) (188-190) or in combination with insulin 
and glucose levels obtained at various time points during an OGTT (OGTT-derived indices) 
(186, 191). Additionally, some of the surrogate IR indices incorporate metabolic and 
demographic parameters, such as TGs (192), FFAs (193), weight, age, BMI, HDL cholesterol, 
fat mass and total cholesterol (194-199) in the equation to improve prediction. 
 
Surrogate indices of IR quantified from fasting samples reflect primarily hepatic insulin 
sensitivity/resistance, whereas OGTT-derived IR indices reflect both peripheral and hepatic 
IR (175, 200). Cross-sectional studies have shown that fasting sample indices explain a 
significant proportion of insulin sensitivity measured by HEC, and are sufficient to provide 
information about IR (187, 201, 202). In contrast, many but not all studies have proposed 
that OGTT-derived indices are more reliable than fasting indices of IR, and their 
correlations with reference methods are stronger than those of fasting insulin and glucose 
derived indices (186, 203-205). One comprehensive study compared 25 insulin sensitivity 
indices, based either on fasting sample indices or OGTT-derived indices with HEC in 272 
non-diabetic Finnish adults. Spearman correlations between HEC and surrogate indices 
that included at least one plasma insulin level were in the range of 0.64-0.77. The strongest  
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correlations were observed with indices containing multiple measures of glucose and 
insulin from the OGTT (r~0.75).  Slightly weaker correlations were observed with indices 
derived from fasting insulin levels (r~0.70), and indices derived from 2-h showed the 
weakest correlation (r~0.65) with HEC (11).  
 
Surrogate indices of IR have demonstrated good ability to predict future type 2 diabetes in 
large cohort studies (182, 206). Furthermore, their correlations with cardiovascular risk 
factors are similar to those of direct measures of IR (207). Strong correlations have also been 
observed between the surrogate indices and intima-media thickness of the carotid artery, a 
marker of atherosclerosis (108). The most commonly used surrogate indices of insulin 
sensitivity or resistance are shown in Table 2.  
 
Table 2. The most commonly used surrogate indices of insulin sensitivity or resistance and their 
correlations with M values in a euglycemic hyperinsulinemic clamp (HEC, modified from 156). 
 
Fasting sample indices 
Index Formula 
Correlations 
with HEC 
Fasting insulin (208) I0 0.63 
HOMA-IR (152) (I0 x G0)/22.5 0.59 
QUICKI (154) 1/[log I0 + log G0] 0.78 
OGTT-derived indices 
Matsuda ISI (168) 104/(G0 x I0 x mean GOGTT x mean IOGTT) 0.5 0.73 
ISI2h (182) 104/I120 x G 120 0.52 
Stumvoll ISI OGTT (159) 0.226 - 0.0032 x BMI - 0.0000645 x I120 - 0.00375 x G90 0.62-0.79 
Belfiore ISI(209)area (155) 2/[(Ia/mean Ia x  Ga/mean Ga)+1] 0.93-0.99 
Gutt ISI0,120 (163) (m*/[G0 + G120/2])/log [(I0+I120)/2] 0.63 
 
BMI, body mass index; G, glucose; Ga, glucose area under the curve; HOMA-IR, The Homeostasis Model 
Assessment of Insulin Resistance; I, insulin; Ia, insulin area under the curve; ISI, insulin sensitivity index, 
OGTT, an oral glucose tolerance test; QUICKI, Quantitative insulin sensitivity check index.* m=(75,000 mg 
+ (fasting glucose - 2h glucose) x 0.19 x body weight)/120 min (glucose in mg/dl; insulin in  μIU/ml). 
 
Similarly to insulin sensitivity indices, insulin secretion indices can be derived from fasting 
plasma insulin and glucose concentrations, as well as from insulin and glucose 
concentrations in an OGTT. Fasting plasma insulin levels have been used to determine 
insulin secretion in many studies, but this approach is biased by a confounding effect of 
hepatic insulin extraction (210, 211). Therefore, the use of proinsulin levels and the ratios of 
proinsulin/insulin and proinsulin/C-peptide have been proposed (212). Another widely 
used assessment of ß-cell function derived from basal measurements of insulin and glucose 
is the homeostatic model assessment (HOMA-B) (188). The Insulin Resistance 
Atherosclerosis Study (IRAS) has demonstrated that HOMA-B underestimates the 
magnitude of ß-cell defect in individuals with IGT and new type 2 diabetes diagnosed by 
OGTT, compared with a direct measure of insulin secretion (213). 
 
In individuals with NGT the amount of secreted insulin in response to glucose is inversely 
correlated with peripheral insulin sensitivity. Increase in IR is accompanied with an 
augmented insulin secretion. Therefore, insulin secretion should be evaluated in the context 
of existing insulin sensitivity. This interrelationship between insulin sensitivity and ß-cell 
secretion has been qualitatively described by a hyperbolic function (Figure 8), and 
quantitatively by the DI proposed by Bergman et al. in 1981 (214, 215). Individuals able to 
compensate their reduced insulin sensitivity with elevated secretion lie on this curve, and 
individuals with altered ß-cell function, people with type 2 diabetes or with IGT, fall off the 
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curve. The DI, which is the product of insulin secretion and insulin sensitivity, takes into an 
account two main factors regulating glucose homeostasis. A low DI has been associated 
with IGT and type 2 diabetes (214, 216), and it also predicts the worsening of 
hyperglycemia (217).  
 
 
 
Figure 8. Hyperbolic relationship between insulin sensitivity and insulin secretion. Under the 
physiological conditions a decrease in insulin sensitivity is compensated by an increase in insulin 
secretion to maintain normoglycemia (1→2), described by a hyperbolic curve. When insulin 
secretion fails to compensate for insulin resistance, the hyperbolic curve shifts to the left and 
abnormal glucose tolerance develops (→3). Modified from (218). 
2.5.2 Glycated hemoglobin (HbA1c) 
 
Glycated hemoglobin is a widely used biomarker of long-term glucose control, reflecting 
exposure to glucose over the previous 2-3 months (219), and it is also an established 
diagnostic criterion for type 2 diabetes. HbA1c is a product of irreversible, non-enzymatic 
glycation where glucose is bound specifically to the N-terminal valine of the hemoglobin β-
chain. Glycation of HbA1c is a passive process depending on erythrocyte lifespan and 
turnover, and blood glucose concentration (220). Increased erythrocyte turnover as 
observed in hemolytic anemia or renal failure results in decreased HbA1c levels. By contrast, 
elevated HbA1c levels have been found in people who have iron deficiency (221, 222), 
vitamin B12 deficiency (223, 224), and in women of reproductive age (225). HbA1c represents 
a minor fraction (normally <6%) of human hemoglobin (226).  
 
Elevated levels of HbA1c predict type 2 diabetes in high-risk populations (227-229). 
Moreover, elevated levels of HbA1c predict long-term micro- and macrovascular 
complications in both non-diabetic and type 2 diabetes individuals (230). A previous study 
has demonstrated that an increase of one unit (%) of HbA1c increases cardiovascular 
mortality by 7.5% in patients with type 2 diabetes (231). Despite the consistent and strong 
association of HbA1c with the development of type 2 diabetes and CVD events, HbA1c has a 
relatively poor concordance with FPG and 2hPG in the diagnosis of type 2 diabetes. 
Additionally, HbA1c levels in the range of 5.7-6.4% are less sensitive in detecting high-risk 
individuals who develop type 2 diabetes than measurements of FPG and 2hPG levels, and 
HbA1c levels add little incremental information on the risk prediction of CVD events 
compared to traditional risk factors (11, 232, 233).  
 
HbA1c levels vary significantly within an individual and between individuals. Intra-
individual variability in HbA1c is considerable smaller than inter-individual variability. The 
18 
 
sources of variation of HbA1c levels are not completely elucidated, but they seem to be 
attributable to both genetic and non-genetic factors. HbA1c levels are highly heritable (47 to 
59%), compared to FPG (34–36%), and 2hPG (33%) levels (234, 235). A recent genome-wide 
association study identified 11 single-nucleotide polymorphisms in 10 different genetic loci 
to be associated with HbA1c levels. They explained approximately 2.4% of the variance in 
HbA1c and 5% of heritability of HbA1c. Some of these loci appear to modulate HbA1c levels 
via non-glycemic factors, including non-glycemic erythrocyte and iron pathways, and some 
of them modulate glycemic physiology (236).  
 
It has been previously shown that only one third of the variance in HbA1c levels in non-
diabetic subjects is attributable to differences in blood glucose levels (237). In addition, only 
moderate correlations of glucose with HbA1c (r=0.26 for correlation between FPG and 
HbA1c, and r=0.14 for correlation between 2hPG and HbA1c) have been observed in non-
diabetic adults (238), which suggests that HbA1c and glucose reflect different processes, 
especially in the non-diabetic range of glucose tolerance. In newly diagnosed type 2 
diabetes patients 2hPG has been shown to be the main contributor to mild hyperglycemia, 
whereas FPG was a predominant contributor to severe hyperglycemia (HbA1c >9%) (239). 
   
Of non-glycemic parameters the most important variables to explain differences in HbA1c 
levels are age and race (240, 241). HbA1c levels increase with age (~0.1% increase per decade 
from 40 years onwards), even after adjustment for sex, FPG and 2hPG (240). Higher HbA1c 
levels have been found in African-Americans than Caucasians across the spectrum of 
glycemia even after the adjustment for plasma glucose and other characteristics known to 
influence HbA1c (242). Also South Asians have higher HbA1c levels than Caucasians, 
independently of FPG and 2hPG levels (243). From lifestyle factors, smoking (244), intake of 
saturated fat and physical inactivity (245, 246) have been associated with elevated levels of 
HbA1c, and low to moderate alcohol intake (247, 248) and vitamin C intake (249) with low 
levels of HbA1c. Some of the studies have demonstrated that HbA1c levels are associated 
with ß-cell dysfunction (250), impaired insulin sensitivity (251) or both (252). 
 
Besides erythrocyte lifespan, glycemia, and other non-glycemic parameters there are also 
erythrocyte related analytical variables that may influence the measurement of HbA1c 
levels. The most important is the presence of hemoglobin variants (HbF, HbS and HbC) that 
might cause spurious HbA1c levels with some assay methods (253). The effect of these 
hemoglobin variants depends on the specific method of analysis, and the results may be 
falsely increased or decreased (254). A summary of factors influencing HbA1c levels are 
shown in Table 3. 
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Table 3. Factors influencing HbA1c levels (modified from 220, 255). 
 
Factor influencing 
HbA1c 
Increased HbA1c Decreased HbA1c 
Variable change in 
HbA1c 
    
Erythropoiesis Iron deficiency, vitamin B12 
deficiency, pregnancy, 
decreased erythropoiesis 
Reticulocytosis, chronic liver 
disease, repletion of iron or 
vitamin B12, administration 
of erythropoietin 
 
 
Erytrocyte 
destruction 
Increased erythrocyte 
lifespan: splenectomy 
Decreased erythrocyte 
lifespan: 
hemoglobinopathies, 
splenomegaly, rheumatoid 
artritis, drugs: 
antiretrovirals, ribavirin, 
dapsone 
 
 
Glycation Alcoholism, chronic renal 
failure, decreased 
erythrocyte pH 
Ingestion of: aspirin, 
vitamin C and E, certain 
hemoglobinopathies, 
increased erytocyte pH 
 
Genetic determinants 
Altered hemoglobin   Fetal hemoglobin 
hemoglobinopathies, 
methemoglobin 
 
Assays Hyperbilirubinemia, 
alcoholism, carbamylated 
hemoglobin, large doses of 
aspirin, chronic opiate use 
Hypertriglyceridemia Hemoglobinopathies 
 
 
 
2.5.3 Lipids, lipoproteins and apolipoproteins  
 
Elevated levels of plasma TGs, large VLDL particles, postprandial TG-rich lipoprotein 
remnants and ApoB, and low levels of HDL cholesterol, characterize and precede type 2 
diabetes by several years (256-259).  
 
Impaired storage of FFAs in adipose tissue, accompanied by increased lipolysis due to IR, is 
responsible for a high flux of FFAs into the liver, resulting in hepatic hypersecretion of 
large VLDL particles and hypertriglyceridemia (260), and simultaneous increases in the 
synthesis rate of ApoB (82). Compositional changes in lipoprotein particles, including the 
formation of atherogenic small dense LDL (sd-LDL) and small HDL (s-HDL) particles and a 
predominance of large VLDL particles, occur in type 2 diabetes. Increased production of 
apolipoprotein CIII is responsible for the inhibition of intravascular lipolysis and impaired 
clearance of postprandial TGs-rich lipoprotein remnants due to reduced activity of heparin 
sulfate proteoglycans (261). Prolonged residence time and compositional changes in 
postprandial TGs-rich remnants sustained by cholesteryl ester transfer protein leads to TGs 
enrichment of LDL and HDL particles, and production of sd-LDL particles (262). 
Alterations in lipoprotein particle concentrations are found already in the pre-diabetic stage 
(263), and approximately 50% of type 2 diabetes individuals have preponderance of sd-LDL 
particles and decreased LDL particle size (264). Individuals with isolated IGT seem to have 
more adverse changes in lipoprotein subclasses than individuals with isolated IFG. IGT is 
associated with increased TGs, large VLDL subclass particles and structural remodeling of 
LDL particles, whereas isolated IFG is characterized by increased ApoB and total LDL 
particles (265). Also gender differences are present in type 2 diabetes, with smaller LDL size 
in women than in men (266). 
 
In prospective studies, high levels of TGs, large VLDL particles, low levels of large HDL 
particles, small mean of LDL and HDL particles, and large mean of VLDL particles have 
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been associated with increased risk of diabetes (259, 267, 268), and IR (151, 263, 269), 
independently of established risk factors, whereas increased levels of large HDL particles 
and ApoA1 (116, 270, 271) have been shown to be protective of diabetes. Several lipoprotein 
ratios have been proposed as potential markers for the future risk of type 2 diabetes (10, 
272). Findings regarding to the predictive ability of lipid variables to predict diabetes have 
been inconsistent. One study showed that ApoB is a better predictor for the future risk of 
type 2 diabetes compared to LDL cholesterol, and HDL cholesterol (273), but another study 
reported that the ApoA1/HDL cholesterol ratio is superior to other lipid variables in 
predicting the development of type 2 diabetes (274).  
 
There is a close relationship between hyperglycemia and lipid abnormalities. The main 
factors linking disturbances in glucose and lipid metabolism are visceral obesity and 
hepatic fat deposition (255). Importantly, insulin and IR play an essential role in 
modulating both lipoprotein and glucose metabolism. Finnish National Diabetes 
Prevention Program (FIN-D2D) reported that out of 10 149 individuals at high risk type 2 
diabetes, 56.2% of men with IFG or IGT had high total cholesterol (≥5.0 mmol/l), 74.6% had 
elevated LDL cholesterol (≥2.5 mmol/l), and 45.5% had elevated total TGs levels. Among 
woman with pre-diabetes 57.7% had elevated total cholesterol, 70.7% elevated LDL 
cholesterol, and 35.8% elevated total TGs (275). However, the role of lipid, lipoprotein and 
apolipopotein variables to predict the worsening of glycemia has not been previously 
systematically evaluated. 
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3 Aims of the Study  
The main aim of this study was to identify new predictors for type 2 diabetes, worsening of 
glycemia, and cardiovascular disease (CVD) in a population-based Metabolic Syndrome in 
Men (METSIM) Study, and to investigate the role of insulin sensitivity and insulin secretion 
in these associations. 
 
 
The specific aims were: 
 
 
1) To investigate the ability of tissue-specific insulin resistance (IR) indices to predict the 
worsening of glycemia, incident type 2 diabetes and CVD disease, and to compare their 
predictive power with that of fasting plasma insulin level. 
 
 
2) To investigate genetic and non-genetic determinants of HbA1c, the most commonly used 
biomarker for type 2 diabetes and hyperglycemia, and to investigate the association of 
HbA1c with insulin secretion and insulin sensitivity. 
 
 
3) To investigate the various lipoprotein and apolipoprotein traits and their ratios as 
predictors for the worsening of glycemia and incident type 2 diabetes, and to investigate 
the associations of these traits and ratios with insulin secretion and insulin sensitivity. 
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4 Subjects, Materials and Methods 
4.1 SUBJECTS 
The Metabolic Syndrome in Men (METSIM) Study includes 10 197 Finnish men aged from 
45 to 70 years and randomly selected from the population register of Kuopio, Eastern 
Finland (population 95 000; including 16 374 men between 45-70 years), and examined in 
2005-2010. In cross-sectional Studies I and II only non-diabetic individuals and individuals 
with newly diagnosed type 2 diabetes at baseline were included, and in Study III non-
diabetic participants without statin treatment at baseline were included. None of the 
participants were on anti-diabetic medication. The characteristics of the study participants 
at baseline are presented in Table 4. 
4.1.1 Baseline study 
 
Studies I and II. A total of 9398 men without diabetes (N=8749) or with newly diagnosed 
diabetes (N=649) were included in Studies I and II (age 57±7 years, body mass index (BMI) 
27.0±4.0 kg/m2, mean±SD). Glucose tolerance status was classified according to the 
American Diabetes Association (ADA) criteria (276, 277). Among participants 3034 (32.3%) 
had normal glucose tolerance, 4344 (46.2%) isolated impaired fasting glucose (IIFG), 312 
(3.3%) isolated impaired glucose tolerance (IIGT), 1059 (11.3%) both IFG and IGT, and 649 
(6.9%) newly-diagnosed type 2 diabetes, defined as FPG ≥7.0 mmol/l and/or 2hPG ≥11.1 
mmol/l. Participants with type 1 diabetes (N=25) or previously diagnosed type 2 diabetes 
(N=763) or with missing OGTT data (N=11) were excluded from all studies.  
 
In Study II, HbA1c levels were measured in 9376 participants. HbA1c categories were 
classified according to the ADA criteria (277) as follows: non-diabetic (HbA1c <5.7%); 
N=4326 (46.1%), pre-diabetic (HbA1c 5.7-6.4%); N=4796 (51.1%), and diabetic (HbA1c ≥6.5%); 
N=254 (2.7%). For selected analyses the pre-diabetics were divided into two groups, early 
pre-diabetics (HbA1c 5.7-6.0%); N=3705 (39.4%), and late pre-diabetics (HbA1c 6.1-6.4%); 
N=1091 (11.6%) category. 
 
Study III. A total of 6607 non-diabetic participants without statin treatment at baseline (age 
56±7 years, body mass index (BMI) 26.6±3.8 kg/m2, mean±SD) were included in statistical 
analyses. Glucose tolerance status was classified according to the American Diabetes 
Association criteria (277) as follows: 2411 (36.5%) participants had normal glucose tolerance 
(106), 3273 (49.5%) isolated impaired fasting glucose (IIFG), 213 (3.2%) isolated impaired 
glucose tolerance (IIGT), and 710 (10.7%) both impaired fasting glucose and impaired 
glucose tolerance (IFG+IGT). Participants with previously diagnosed type 1 diabetes 
(N=25), type 2 diabetes (N=763), participants receiving statin treatment at baseline 
(N=2,142) or participants with missing OGTT data (N=11) were excluded from this study.  
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Table 4. Characteristics of non-diabetic METSIM participants at baseline. 
 
Trait at baseline  N  Mean ± SD  Range 
Age (years)  9398  57.3 ± 7.1  45 - 74 
BMI (kg/m2)  9395  27.0 ± 4.0  16.2 - 55.4 
Fat mass (%)  9376  23.7 ± 6.4  1.6 - 52.8 
Systolic BP (mmHg)  9398  137.9 ± 16.6  86.0 - 236.0 
Diastolic BP (mmHg)  9398  87.5 ± 9.4  56.0 - 130.0 
hs-CRP (mg/l)  9397  2.1 ± 4.2  0.1 - 214.8 
IL1-RA (pg/ml)  9397  221.1 ± 176.9  31.0 - 3890.2 
Adiponectin (μg/ml)  9396  7.9 ± 4.4  1.0 – 112.60 
FFA AUC (mmol/l*min)  9357  22.9 ± 10.0  3.15 - 153.30 
FPG (mmol/l)  9398  5.8 ± 0.7  3.5 - 20.0 
2hPG (mmol/l)  9396  6.4 ± 2.4  1.4 - 38.2 
HbA1c (%)  9376  5.7 ± 0.4  3.4 - 14.2 
Matsuda ISI (mg/dL, mU/L)       9337  6.7± 4.2  0.5 - 42.5 
Disposition index  9337  156.5 ± 74.4  6.4 - 1304.06 
Total cholesterol (mmol/l)  9397  5.4 ± 1.01  1.9 - 16.5 
LDL cholesterol (mmol/l)  9394  3.4 ± 0.9  0.7 - 7.9 
HDL cholesterol (mmol/l)  9395  1.5 ± 0.4  0.1 - 3.9 
Total TGs (mmol/l)  9397  1.4 ± 1.0  0.3- 37.6 
ApoA1 (g/l)  9395  1.4 ± 0.2  0.3 - 3.0 
ApoB (g/l)  9395  1.0 ± 0.3  0.2 - 2.7 
 
Abbreviations: 2hPG, 2-hour plasma glucose during an OGTT; ApoA1, Apolipoprotein A-I; ApoB, 
Apolipoprotein B; AUC, area under the curve; BMI, body mass index; BP, blood pressure; FFA, free fatty 
acids; FPG, Fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; hs-CRP, 
high-sensitivity C-reactive protein; IL1-RA, interleukin 1 receptor antagonist; ISI, insulin sensitivity index; 
LDL, low-density lipoprotein; SD, standard deviation; TGs, triglycerides. 
4.1.2 Follow-up studies (Study I and III) 
 
A total of 4806 individuals of the 8749 non-diabetic participants at baseline have been re-
examined once in the ongoing prospective follow-up study since 2010 (mean follow-up 
time of 5.9 years; range of follow-up time: 0.8-7 years).  
 
Diagnosis of incident type 2 diabetes (Study I and III) 
 
Study I. Amongst the 8749 nondiabetic men at baseline, 558 developed incident type 2 
diabetes between the date of the baseline METSIM study and 31st of December 2013. 
Diagnosis of new-onset type 2 diabetes was based on: 1) an OGTT or HbA1c ≥6.5% (297 new 
cases of diabetes) amongst 4806 nondiabetic individuals who participated in the ongoing 
follow-up study in 2010–2013, or 2) antidiabetic medication started between the baseline 
study and 31st of December 2013 (261 new cases of diabetes; information obtained from the 
National Drug Reimbursement registry for all 8749 nondiabetic participants). 
 
Study III. Statistical analyses included 6607 non-diabetic participants without statin 
treatment at baseline (Figure 9). A total of 386 of them developed incident type 2 diabetes 
during a 5.9 year follow-up (range of follow-up: 0.8-7 years). The information on incident 
type 2 diabetes was obtained from the METSIM follow-up data (OGTT and HbA1c, N=135) 
or from the National Drug Reimbursement registry (N=251). 
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Diagnosis of CVD events (Study I) 
 
Out of 8749 non-diabetic individuals at baseline, 239 had a CVD event between the date of 
the baseline METSIM Study and 31st of December 2013. The incident CVD event was 
defined as non-fatal myocardial infarction, coronary heart disease death, or fatal and non-
fatal cerebral infarction which occurred between the baseline study and 31st of December 
2013. CVD events were defined according to the internationally accepted criteria (278, 279) 
and verified from the hospital records. Individuals with non-fatal myocardial infarction 
(N=344) and stroke (N=194) before the baseline were excluded from statistical analyses. 
 
All studies were approved by the Ethics Committee of the University of Eastern Finland 
and Kuopio University Hospital and were conducted in accordance with the Helsinki 
Declaration. All study participants provided written informed consent. 
 
 
*Data on incident type 2 diabetes and CVD events have been collected from METSIM follow-up, National 
Drug Reimbrusment registry and medical records (the coverage of the follow-up data with respect to 
diagnosis of incident type 2 diabetes and CVD events is 100%). 
 
Figure 9. Study subjects included in the Studies I-III. 
4.2 MATERIALS AND METHODS 
Measurements (Studies I-III) 
 
Height was measured without shoes to the nearest 0.5 cm. Weight was measured in light 
clothing with a calibrated digital scale (Seca 877, Seca, Hamburg, Germany), and rounded 
up to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg) divided by 
height squared. Waist was measured to the nearest 0.5 cm as the average of two 
measurements taken after inspiration and expiration at the midpoint between the lowest rib 
and iliac crest). Hip circumference (at the level of the trochanter major) was measured to 
the nearest 0.5 cm. Body composition was determined by bioelectrical impedance 
(Bioimpedance Analyzer Model BIA 101, Akern SrL, Florence, Italy) in subjects in the 
supine position after a 12-h overnight fast. Three measurements (interval between the 
measurements: 1.5 min) of blood pressure were performed in the sitting position after a 10-
min rest with mercury sphygmomanometer. The average of three measurements was used 
to calculate systolic and diastolic blood pressure.  
 
 
25 
 
Oral glucose tolerance test (Studies I-III) 
 
Glucose tolerance status was evaluated with a 2h OGTT (75g of glucose) after 12h overnight 
fast at baseline and follow-up studies according to the World Health Organization  
standard (280). Samples for glucose insulin and FFAs were drawn at 0, 30 and 120 min, and 
glucose tolerance was classified according to the ADA criteria (276, 277). 
   
Laboratory measurements (Studies I-III) 
 
Plasma glucose was measured by an enzymatic hexokinase photometric assay (Konelab 
Systems reagents, Thermo Fisher Scientific; Vantaa, Finland). Insulin was determined by 
immunoassay (ADVIA Centaur Insulin IRI no. 02230141; Siemens Medical Solutions 
Diagnostics, Tarrytown, NY). Blood HbA1c was analyzed by high-performance liquid 
chromatography (HPLC) using Tosoh G7 glycohemoglobin analyzer (Tosoh Bioscience, Inc. 
San Francisco, CA, USA) and calibrated according to the DCCT Standard (281). Total 
cholesterol, LDL cholesterol, HDL cholesterol and total TGs were measured by enzymatic 
colorimetric tests (Konelab Systems Reagents). Serum concentrations of high-sensitivity C-
reactive protein (hs-CRP) were assayed by kinetic imunoturbidimetry (NIPIA; Immage 
Imunochemistry System, Beckman Coulter, Fullerton, CA, USA); alanine 
aminotransferase(ALT) by an enzymatic photometric test (Konelab Reagent System) and 
plasma interleukin 1 receptor antagonist (IL1-RA) by photometric immunoassay (ELISA), 
method (Quantikine DRA00 Human IL-1RA, R&D Systems Inc., Minneapolis, MN, USA). 
Plasma free fatty acids (FFAs) were measured by enzymatic colorimetry (Konelab Systems 
reagents, Thermo Fisher Scientific; Vantaa, Finland). Plasma adiponectin was measured by 
an enzyme-linked imunosorbent assay (ELISA) (Human Adiponectin ELISA Kit; Linco 
Research, St Charles, MI, USA) and apolipoproteins A1 and B (ApoA1 and ApoB) by 
imunoturbidimetry (Konelab Systems Reagents). Typical coefficients of variation (CV%; 
intra-assay, inter-assay, respectively) for the selected measurements were as follows: 
glucose: 2.7 %, 1.8 %; insulin: 3.7 %, 5.3 %; LDL cholesterol: 3.3 %, 2.9 %; ALT: 5.8 %, 2.4 %; 
Adiponectin: 12.8 %, 13.9 %. 
 
Genotyping and genetic risk score for HbA1c (Study II) 
In Study II, genotyping of 11 SNPs associated with HbA1c levels in a genome-wide 
association study (236) was performed using HumanExome-12v1.1 chip (Illumina) or 
HumanOmniExpress-12v1 chip (Illumina). All SNPs were in Hardy-Weinberg equilibrium. 
The weighted genetic risk score for HbA1c (GRS) was calculated as a sum of risk alleles 
multiplied by their respective effect sizes, further divided by 2 x sum of all effect sizes and 
then multiplied by 22 (total number of alleles). The GRS was available for 8779 subjects. 
Lipoprotein subclass measurements (Study III) 
In Study III, lipoprotein subclasses were analyzed by proton NMR spectroscopy in native 
serum samples as previously described (282-284). The subclasses were defined as follows: 
chylomicrons and largest VLDL particles (CM/lar-VLDL, average particle diameter ≥75 
nm), five subclasses of VLDL: very large VLDL (vl-VLDL; 64.0 nm), large VLDL (l-VLDL; 
53.6 nm), medium-size VLDL (m-VLDL; 44.5 nm), small VLDL (s-VLDL; 36.8 nm), and very 
small VLDL (vs-VLDL; 31.3 nm); IDL (28.6 nm); three LDL subclasses: large LDL (l-LDL; 
25.5 nm), medium-size LDL (m-LDL, 23.0 nm), and small LDL (s-LDL; 18.7 nm); and four 
HDL subclasses: very large  HDL (vl-HDL; 14.3 nm), large HDL (l-HDL, 12.1 nm), medium-
size HDL (m-HDL; 10.9 nm), and small HDL (s-HDL, 8.7 nm). The following components of 
the lipoprotein subclasses were quantified: phospholipids (PL), triglycerides (TGs), 
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cholesterol (C), free cholesterol (FC), and cholesterol esters (CE). Because of the resolution 
of the method, not all of these components were available for every subclass. 
Calculations 
The trapezoidal method was used to calculate the Glucose AUC (Studies I-III) and FFA 
AUC (Study II) in an OGTT based on the samples collected at 0, 30, and 120 min. 
Calculations of the Matsuda insulin sensitivity index (Matsuda ISI) (170) and early-phase 
insulin secretion (16) from an OGTT (InsAUC0-30/GluAUC0-30) have been previously 
described. DI was calculated as Matsuda ISI x InsAUC0-30/Glu AUC0-30 (Studies I-III). In 
Study I, the Adipocyte IR index was defined as the product of fasting FFAs and fasting 
plasma insulin levels (193). The previously validated Liver IR index (Liver IR) was 
calculated (285). For consistency with other indices expressed as IR in Study I, the Matsuda 
IR was calculated as 10/Matsuda ISI. In Study III, non-HDL cholesterol was calculated by 
subtracting HDL cholesterol from total cholesterol. 
Statistical analyses 
Statistical analyses were conducted using IBM SPSS version 19 (SPSS, Chicago, IL).  All 
traits except for age (Studies I-III) and LDL cholesterol, total cholesterol and the GRS (Study 
II) were log 10-transformed to correct for their skewed distribution. Normality of the 
distribution was tested by the Kolmogorov-Smirnov test (Studies I-III). Fisher´s r-to-z 
transformation was used to test statistical differences between beta coefficients of tissue-
specific IR indices and insulin (Study I), and between the correlation coefficients (Study II). 
Continuous traits were compared across the glucose tolerance subgroups (Studies I and III) 
and across the HbA1c subgroups (Study II) using one-way ANOVA with Bonferroni post-
hoc test. Categorical variables were compared using chi-squared test. Linear regression was 
used to adjust for age. 
Study I. Surrogate indices of IR and fasting plasma insulin levels were compared across the 
FPG and 2hPG categories using one-way ANOVA and ANCOVA to adjust for confounding 
factors (age, BMI). Linear regression was used to evaluate the ability of indices and insulin 
to predict the worsening of glycemia. The results are presented as unstandardized effect 
sizes (B and SE) and standardized beta coefficients. Cox regression was used to evaluate the 
ability of indices and insulin to predict incident type 2 diabetes and CVD events. Hazard 
ratios (HRs) are presented with 95% confidence intervals (CI). After the Bonferroni 
correction for multiple comparisons P<0.0125 was considered as statistically significant. 
Study II. Pearson correlation analysis was performed to evaluate the correlations of 
selected variables of interest. Forward stepwise multiple linear regression analysis was 
used to identify variables, which explained the variance in HbA1c, 2hPG and FPG levels 
among participants without type 2 diabetes. The following independent variables were 
entered into the model: age, FPG, 2hPG, BMI, fat mass %, HDL cholesterol, total TGs , ALT, 
adiponectin, hs-CRP, IL1-RA, FFA AUC, systolic BP, Matsuda ISI, the DI, current smoking 
(yes/no), physical activity (physically active vs. physically inactive), and the GRS. Strongly 
inter-correlated variables (r≥0.6) from regression analyses (expect for FPG and the DI which 
were included) were excluded. Results were presented as standardized beta coefficients 
and adjusted R2 provided information about the variation in HbA1c levels explained by the 
complete model and partial models at each steps of the stepwise liner regression analysis. 
Study III. The t-test for independent samples was used to compare the differences between 
individuals without diabetes and individuals with incident type 2 diabetes. The results are 
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given as mean±SD. Linear regression analysis was used to evaluate lipoprotein and 
apolipoprotein traits and subclasses at baseline as predictors for the worsening of glycemia 
(Glucose AUC), insulin sensitivity and insulin secretion at follow-up. Results are presented 
as standardized coefficients beta±SD. Cox regression analysis was used to evaluate the 
ability of lipoprotein and apoliporotein concentrations to predict incident type 2 diabetes. 
Hazard ratios per SD unit are presented with their 95% CI. P value<0.0015 was considered 
statistically significant given the 33 tests performed (11 lipoprotein and apolipoprotein 
traits and three different models for each trait). For the associations of lipoprotein 
subclasses and particle components with the worsening of glycemia P<0.0008 was 
considered statistically significant (given 60 traits tested), and P<0.05 was considered 
nominally significant.  
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5 Results  
5.1 MARKERS OF TISSUE-SPECIFIC INSULIN RESISTANCE AS 
PREDICTORS OF WORSENING OF GLYCEMIA, INCIDENT TYPE 2 
DIABETES AND CARDIOVASCULAR DISEASE EVENTS (STUDY I) 
This study evaluated the ability of three validated tissue-specific IR indices (Matsuda IR, 
Adipocyte IR and Liver IR) compared to fasting insulin to predict deterioration of glycemia, 
incident type 2 diabetes and  CVD events in a 5.9-year follow-up of the METSIM Study. 
 
Insulin resistance indices and fasting plasma insulin levels as predictors for the 
worsening of glycemia 
 
In the linear regression model Matsuda IR, Adipocyte IR, Liver IR and fasting plasma 
insulin levels significantly predicted an increase in FPG, 2hPG and Glucose AUC at the 5.9-
year follow-up (Table 6). Matsuda IR and Adipocyte IR were the best predictors of 2hPG 
and Glucose AUC. Adjustment for confounding factors (age, BMI, smoking, physical 
activity, alcohol consumption and family history of type 2 diabetes) attenuated, but did not 
abolish the associations. Additional adjustment for the DI and Glucose AUC at baseline 
abolished the predictive value of Adipocyte IR and Liver IR in predicting FPG. Matsuda IR 
and Adipocyte IR were significantly better predictors of 2hPG and Glucose AUC than were 
fasting plasma insulin levels.  
 
Insulin resistance indices and fasting plasma insulin levels as predictors of incident type 
2 diabetes and CVD events 
 
During the mean 5.9-year follow-up 558 of 8749 non-diabetic men at baseline developed 
incident type 2 diabetes and 239 men had a CVD event. In unadjusted Cox regression 
models all tissue-specific IR indices and fasting plasma insulin levels significantly predicted 
an increased risk of incident type 2 diabetes (Table 7) and incident CVD events (Table 8). 
Liver IR was the strongest predictor of both incident type 2 diabetes (HR=1.83, 95% CI:1.68-
1.98, P=3.80x10-46) and CVD events (HR=1.31, 95% CI:1.15-1.48, P=4.0x10-5). Matsuda IR, 
Adipocyte IR and fasting plasma insulin levels had comparable ability to predict incident 
type 2 diabetes and CVD events.  
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Table 6. Tissue-specific insulin resistance indices and fasting plasma insulin as predictors of 
glycemia at the 5.9-year follow-up in the METSIM study. 
 
FPG at follow-up 
Index at baseline B SE Beta P Pa Pb Pc Pd 
Matsuda IR 0.038 0.002 0.280 1.5E-81 3.4E-39 3.8E-13 5.8E-07 4.3E-07 
Adipocyte IR 0.028 0.002 0.248 9.4E-64 6.2E-25 0.015 0.001 0.217 
Liver IR  0.264 0.020 0.196 5.2E-40 2.1E-06 8.9E-08 0.733 2.0E-03 
Fasting plasma insulin 0.036 0.002 0.248 4.1E-64 1.3E-24 2.9E-04 1.4E-08 6.5E-04 
Index at baseline 
2hPG at follow-up 
B SE Beta P Pa Pb Pc Pd 
Matsuda IR 0.150 0.007 0.312 1.0E-101 1.6E-53 3.0E-19 5.6E-07 4.4E-07 
Adipocyte IR 0.126 0.006 0.319 8.1E-106 5.5E-59 6.9E-16 1.2E-14 7.0E-10 
Liver IR  1.276 0.068 0.269 3.7E-75 2.1E-23 1.4E-28 2.1E-06 1.3E-13 
Fasting plasma insulin 0.132 0.007 0.262 2.4E-71 9.5E-32 6.5E-06 1.3E-09 2.8E-05 
Index at baseline 
Glucose AUC at follow-up 
B SE Beta P Pa Pb Pc Pd 
Matsuda IR 0.091 0.004 0.361 2.5E-137 4.0E-77 7.9E-28 7.9E-04 7.5E-04 
Adipocyte IR 0.073 0.003 0.356 8.0E-133 1.0E-73 2.4E-15 1.2E-08 1.2E-05 
Liver IR  0.685 0.036 0.277 4.3E-79 1.2E-21 2.4E-29 0.063 9.1E-05 
Fasting plasma insulin 0.077 0.004 0.294 5.6E-90 1.5E-39 6.6E-05 3.7E-07 4.4E-04 
 
Abbreviations: B, unstandardized effect size; Beta, standardized regression coefficient; FPG, fasting plasma 
glucose; Glucose AUC, glucose area under the curve; 2hPG, 2-hour plasma glucose; IR, insulin resistance; 
SE, standard error. Linear regression analysis. N=4474 for FPG and 2hPG, and 4450 for Glucose AUC. Bold 
font indicates statistical significance P<0.0125. P, adjusted for follow-up time. Pa, adjusted for follow-up time, 
age, BMI, smoking, physical activity, alcohol consumption and family history of type 2 diabetes. Pb, adjusted 
for follow-up time, age, BMI, smoking, physical activity, alcohol consumption, family history of type 2 
diabetes, and DI at baseline. Pc, adjusted for follow-up time age, BMI, smoking, physical activity, alcohol 
consumption, family history of type 2 diabetes and Glucose AUC at baseline. Pd, adjusted for follow-up time, 
age, BMI, smoking, physical activity, alcohol consumption, family history of type 2 diabetes, DI and Glucose 
AUC at baseline. 
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5.2 GLYCATED HEMOGLOBIN LEVELS AND GLYCEMIC AND NON-
GLYCEMIC MEASURES IN 9398 FINNISH MEN WITHOUT DIABETES 
(STUDY II) 
This study investigated the glycemic and non-glycemic determinants of HbA1c, and the 
association between HbA1c levels and insulin sensitivity and insulin secretion in non-
diabetic participants and newly diagnosed type 2 diabetes participants of the baseline 
METSIM Study. 
 
Clinical and laboratory traits explaining the variance in HbA1c levels 
 
Stepwise forward multiple linear regression analysis, which included 18 traits, was 
performed to identify traits which best explain the variance in HbA1c in non-diabetic 
participants (Table 9). The final model explained 17% of the variance in HbA1c levels.  The 
strongest determinants of HbA1c levels were age, FPG and hs-CRP, and they explained ~6%, 
5% and 2% of the variance of HbA1c levels, respectively. The contribution of Matsuda ISI 
and DI to HbA1c levels was small (<2%). A greater proportion of the variance was explained 
by non-glycemic variables (11%). In contrast, a similar model for FPG and 2hPG showed 
that the DI, the Matsuda ISI and 2hPG or FPG explained together 43% and 47% of the total 
44% and 51% variance in FPG and 2hPG, respectively, in non-diabetic participants. In the 
participants with newly diagnosed type 2 diabetes, FPG and 2hPG together explained 61% 
of the total 64% variance in HbA1c, respectively (results not shown). 
 
Differences in Matsuda insulin sensitivity index and Disposition index between the 
categories of HbA1c and glucose tolerance   
 
The differences in insulin sensitivity (Matsuda ISI) and DI across the four categories of 
HbA1c or five glucose tolerance categories are shown in Figure 10. Within the categories of 
HbA1c, Matsuda ISI significantly decreased in both pre-diabetes categories (-16% and -35%, 
respectively) and diabetes category (-49%) compared to the reference category 
(POVERALL<0.001). The DI also significantly decreased across the HbA1c categories, in the early 
pre-diabetes (-11%), late pre-diabetes (-29%) and diabetes categories (-57%), compared to 
the reference category (POVERALL< 0.001). Matsuda ISI significantly decreased by 31-63% 
across the glucose tolerance categories, compared to the NGT category (POVERALL<0.001). 
Similarly, the DI significantly decreased across the glucose tolerance categories by 29-71%, 
compared to the NGT category (POVERALL<0.001). Changes in Matsuda ISI and the DI were 
larger across the glucose tolerance categories than across the HbA1c categories (Figure 10 C).   
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Table 9. Multiple forward linear regression analysis explaining the variance in HbA1c levels in 
non-diabetic participants of the baseline METSIM study. 
   
    HbA1c (N=8088) 
Independent Variables Beta P Adj.R2 (%)* 
Adj.R2 change 
(%)# 
Age (years) 0.264 <0.001 5.6 5.6 
FPG (mmol/l) 0.089 <0.001 9.8 4.2 
hs-CRP (mg/l) 0.079 <0.001 11.6 1.8 
Genetic risk score 0.135 <0.001 13.3 1.7 
Smoking 0.113 <0.001 14.4 1.1 
Matsuda ISI -0.081 <0.001 15.7 1.3 
Disposition index -0.090 <0.001 16.2 0.5 
Systolic BP (mmHg) -0.059 <0.001 16.5 0.3 
BMI (kg/m2) 0.093 <0.001 16.7 0.2 
Physical activity -0.041 <0.001 16.9 0.2 
Fat mass (%) -0.047 0.006 17.0 0.1 
ALT (U/l) -0.031 0.008 17.0 <0.1 
2hPG (mmol/l) 0.034 0.018 17.1 0.1 
FFA AUC (mmol/l*min) -0.029 0.014 17.1 <0.1 
Total TGs (mmol/l)   0.023 0.047 17.1 <0.1 
 
Abbreviations: ALT, alanine-aminotransferase; Adj.R2, Adjusted R-Squared; AUC, area under the curve; 
Beta, standardized coefficient; BMI, body mass index; BP, blood pressure; FFA, free fatty acids; GRS, 
Genetic risk score for HbA1c; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; hs-CRP, high-
sensitivity C-reactive protein; TGs, triglycerides.  
 
*Adjusted R2 gives the proportion of the variation in the dependent variable (HbA1c) explained by the 
independent variables. 
#Adjusted R2 change gives the increase in the variation explained by each independent variable added into 
the model. 
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Figure 10. Comparison of changes in insulin sensitivity (Matsuda ISI, open bars) and insulin 
secretion (Disposition index calculated as Matsuda ISI x InsAUC0-30/GluAUC0-30, black bars): A. 
HbA1c categories; B. Glucose tolerance categories based on the glycemic criteria (American 
Diabetes Association criteria in 2003); C. Pre-diabetes and newly diagnosed type 2 diabetes 
categories defined by the glucose or HbA1c criteria. Bars show percentages of the means 
respective to the reference category as follows: the reference category for HbA1c categories was 
HbA1c<5.7%, and the reference category for the glucose tolerance categories was normal 
glucose tolerance (FPG<5.6 mmol/l and 2hPG<7.8 mmol/l). #P<0.0001 for the overall 
comparison across the categories. ***P<0.001 compared with the corresponding reference 
category. 
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5.3 ASSOCIATIONS OF MULTIPLE LIPOPROTEIN AND APOLIPOPROTEIN 
MEASURES WITH WORSENING OF GLYCEMIA AND INCIDENT TYPE 2 
DIABETES IN 6607 NON-DIABETIC FINNISH MEN (STUDY III) 
In this study various lipoprotein and apolipoprotein traits and their ratios were evaluated 
as predictors for the worsening of glycemia, incident type 2 diabetes, IR and insulin 
secretion in the 5.9-year follow-up study of the METSIM cohort.  
 
Lipoprotein traits as predictors for the worsening of glycemia  
 
ApoA1, ApoB, small LDL particles, small VLDL particles, large VLDL particles, and the 
lipoprotein/lipoprotein ratios predicted an increase in Glucose AUC, whereas large HDL 
particles predicted reduced Glucose AUC at follow-up. The ApoB/LDL cholesterol ratio 
was the strongest predictor of Glucose AUC after adjustment for age, BMI, smoking and 
physical activity. Also high concentrations of ApoB, large VLDL particles, and the 
ApoA1/HDL cholesterol ratio were associated with an increase in Glucose AUC (Table 10).  
 
Lipoprotein traits as predictors of incident type 2 diabetes 
 
A total of 386 of 6607 non-diabetic participants without statin treatment at baseline 
developed incident type 2 diabetes (Table 11). The ApoA1/HDL cholesterol ratio was the 
strongest predictor of incident diabetes after adjustment for confounding factors (HR=1.27, 
CI 1.15-1.39, P<0.001). Additional adjustment for Matsuda ISI or DI attenuated or abolished 
all significant associations of lipoprotein traits and incident type 2 diabetes. 
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Table 10. Lipoproteins and apolipoproteins and their ratios as predictors of Glucose AUC at the 
5.9-year follow-up of the METSIM cohort. 
 
 
 
Glucose AUC at follow-up 
Trait at baseline  N Beta SE P 
ApoA1(g/l) 3330 0.058 0.017 6.0E-04 
ApoB (g/l) 3330 0.105 0.017 1.5E-09 
LDL cholesterol (mmol/l)  3330 0.041 0.017 0.016 
Small LDL particles (μmol/l)  3269 0.065 0.017 1.3E-04 
HDL cholesterol (mmol/l)  3330 -0.024 0.018 0.167 
Large HDL particles (μmol/l)  3268 -0.084 0.018 2.4E-06 
Small VLDL particles (μmol/l)  3269 0.078 0.018 1.0E-05 
Large VLDL particles (μmol/l)  3217 0.101 0.018 1.3E-08 
ApoA1/HDL cholesterol ratio  3330 0.100 0.018 1.9E-08 
ApoB/LDL cholesterol ratio  3330 0.113 0.017 4.2E-11 
ApoB/non-HDL cholesterol ratio*  3330 0.086 0.017 4.1E-07 
 
Abbreviations: ApoA1, apolipoprotein A-I; ApoB, apolipoprotein; AUC, area under the curve; Beta, 
standardized regression coefficient; HDL, high-density lipoprotein; LDL, low-density lipoprotein; *Non-HDL 
cholesterol = (total cholesterol - HDL cholesterol); SE, standard error; VLDL, very-low-density lipoprotein.  
P<0.0015 was considered statistically significant (marked by bold font) given the 33 traits tested, and 
P<0.05 was considered nominally significant (underlined). P, adjusted for age, BMI, smoking, physical 
activity and follow-up time.  
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Associations of lipoprotein traits at baseline with insulin sensitivity and insulin secretion 
at follow-up 
 
In linear regression analysis all lipoprotein traits measured at baseline were significantly 
associated with insulin sensitivity and insulin secretion at follow-up (except for the 
association of ApoA1 with insulin secretion) after adjustment for confounding factors (Table 
12). Large HDL particles and HDL cholesterol were the strongest predictors of greater insulin 
sensitivity at follow-up, whereas the ApoA1/HDL cholesterol ratio was the strongest 
predictor of lower insulin sensitivity and insulin secretion at follow-up.  
 
Table 12. Associations of lipoproteins and apolipoproteins and their ratios at baseline with insulin 
sensitivity and insulin secretion measured at the 5.9- year follow-up of the METSIM cohort. 
 
Index at follow-up 
Matsuda ISI  Disposition index 
Trait at baseline N Beta SE P  N Beta SE P 
ApoA1 (g/l) 3324 0.104 0.015 <0.001  3324 -0.011 0.017 0.539 
ApoB (g/l) 3324 -0.133 0.016 <0.001  3324 -0.094 0.018 <0.001 
LDL cholesterol (mmol/l) 3324 -0.049 0.016 <0.001  3324 -0.046 0.017 0.008 
Small LDL particles (μmol/l) 3263 -0.062 0.016 <0.001  3263 -0.056 0.017 <0.001 
HDL cholesterol (mmol/l) 3324 0.199 0.016 <0.001  3324 0.062 0.018 <0.001 
Large HDL particles (μmol/l) 3262 0.216 0.016 <0.001  3262 0.077 0.018 <0.001 
Small VLDL particles (μmol/l) 3263 -0.161 0.016 <0.001  3263 -0.074 0.018 <0.001 
Large VLDL particles (μmol/l) 3263 -0.181 0.016 <0.001  3263 -0.090 0.018 <0.001 
ApoA1/HDL cholesterol ratio 3311 -0.194 0.016 <0.001  3311 -0.107 0.018 <0.001 
ApoB/LDL cholesterol ratio 3325 -0.147 0.016 <0.001  3325 -0.086 0.017 <0.001 
ApoB/non-HDL cholesterol ratio* 3325 -0.096 0.016 <0.001  3325 -0.063 0.017 <0.001 
 
Abbreviations: ApoA1, apolipoprotein A-I; ApoB, apolipoprotein; Beta, standardized regression coefficient; 
HDL, high-density lipoprotein; ISI, insulin sensitivity index; LDL, low-density lipoprotein; *Non-HDL 
cholesterol (calculated as: total cholesterol - HDL cholesterol); SE, standard error; VLDL, very-low-density 
lipoprotein. Linear regression analysis, standardized coefficients (Beta, SE) are presented. P values were 
adjusted for age, BMI, smoking, physical activity and follow-up time. P<0.0015 was considered as statistically 
significant given the 33 traits tested (marked by bold font), and P<0.05 was considered as nominally 
significant (underlined). 
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6 Discussion 
6.1 REPRESENTATIVENESS OF THE STUDY POPULATION AND METHODS 
This study was based on the well-characterized large population-based METSIM cohort 
(N=10 197, participation rate of ~62.3%) with a follow-up period of 5.9 years (range 0.8-7 
years). The METSIM Study included participants from the entire spectrum of glucose 
tolerance. 
 
Studies I and II included 9938 non-diabetic or newly diagnosed type 2 diabetes participants 
at baseline from the METSIM cohort. In Study II, HbA1c levels were measured in 9376 
participants. Furthermore, genotyping of 11 SNPs associated with HbA1c levels was 
performed, and the GRS for 8779 individuals was calculated. The large sample size allowed 
the identification of the main determinants of HbA1c. Detailed proton NMR spectroscopy 
was applied to analyze lipoprotein subclasses in native serum samples in Study III. All 
study participants had a one-day outpatient visit to the Clinical Research Unit at the 
University of Kuopio at both baseline and follow-up, which included an interview on 
history of chronic diseases, drug treatment and lifestyle factors such as physical activity, 
smoking and alcohol consumption. 
 
A 5.9-year follow-up period enabled the evaluation of the role of tissue-specific markers of 
IR and lipoprotein traits and the ratios in predicting the worsening of glycemia, incident 
type 2 diabetes and CVD events. Diagnosis of type 2 diabetes at the follow-up study was 
based either on FPG or 2hPG in an OGTT or HbA1c criteria. Hyperglycemia was measured 
as a continuous trait. Data regarding CVD events were available for 8749 non-diabetic 
participants at baseline and were verified from the hospital records. 
  
A limitation of the METSIM study is that it includes only middle-aged Finnish men. Thus, 
the replication of our results in other populations and women is needed. Although direct 
measures of insulin sensitivity (euglycemic clamp, radiolabelled glucose) and insulin 
secretion (FSIVGTT) are more accurate, the application of these methods was not possible 
due to the large sample size of the METSIM Study. However, the indices of insulin 
sensitivity and insulin secretion previously validated against the clamp were applied (16). 
The Matsuda IR, based on three measurements (0, 30, 120 min) during an OGTT was 
calculated as 10/Matsuda ISI. The Matsuda ISI based on five and three measurements has a 
correlation of r=0.985 with the M value from the clamp. Therefore Matsuda IR reliably 
reflects skeletal muscle IR. Adipocyte IR index was calculated as the product the fasting 
plasma insulin concentration and fasting plasma FFAs concentration, and as a marker of 
hepatic IR was used previously validated index of Liver IR, which has a correlation of 0.65 
with a product of tracer-measured hepatic glucose production and fasting insulin. It has 
been shown that both Adipocyte IR and Liver IR indices are significantly associated with 
FPG and 2hPG, and they gradually increased with higher levels of FPG and 2hPG within 
the non-diabetic range of glycemia (286). This suggests that they provide information about 
IR in adipose tissue and liver. HbA1c levels are known to be affected by hemoglobin 
concentration and by iron- and vitamin B12 deficiency, but unfortunately these variables 
were not measured in the METSIM Study.  
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6.2 PREDICTIVE VALUE OF DIFFERENT MARKERS OF INSULIN 
RESISTANCE FOR TYPE 2 DIABETES, WORSENING OF GLYCEMIA AND 
AND CARDIOVASCULAR EVENTS (STUDIES I AND III) 
IR is an important predictor for the development of type 2 diabetes and contributes to an 
elevated risk of CVD events. To understand the link between the markers of IR and their 
association with type 2 diabetes and glycemia it is important to take into account that IR 
manifests itself differently in different tissues, including skeletal muscle, liver and adipose 
tissue. Insulin is relevant not only for glucose uptake, but also for the suppression of FFA 
release from adipose tissue, which limits hepatic TGs synthesis, maintains normal 
endothelial and coagulation homeostasis, and down-regulates inflammatory pathways (43, 
98). Moreover, insulin regulates crosstalk between liver, muscle, adipose tissue and several 
CVD risk factors. Previous studies have not investigated the association of different 
markers of tissue level IR with conversion to type 2 diabetes, worsening of glycemia or 
incident CVD events and compared their predictive power with that of fasting insulin 
levels in large prospective settings.   
 
Our 5.9-year follow-up study (Study I) showed that Matsuda IR (representing IR in skeletal 
muscle), Adipocyte IR (adipocyte IR), Liver IR (hepatic IR) and fasting plasma insulin levels 
significantly predicted the worsening of glycemia and type 2 diabetes independently of 
confounding factors. All markers of IR predicted and increased risk of CVD events. 
Compared to fasting plasma insulin level tissue-specific markers of IR, Matsuda IR and 
Adipocyte IR were significantly better predictors of 2hPG, Glucose AUC and incident type 
2 diabetes after adjustment for confounding factors (age, BMI, smoking, physical activity, 
alcohol consumption, family history of diabetes, insulin secretion and baseline glycemia). 
Liver IR was the strongest predictor of both incident type 2 diabetes and CVD events.                            
                                            
Only a few studies have systematically compared the predictive power of insulin 
sensitivity/resistance indices in predicting type 2 diabetes in larger cohorts (182, 206). The 
Gutt insulin sensitivity index consistently demonstrated the best overall ability to predict 
diabetes among the IR indices tested. (206). Also other indices such as Quantitative insulin 
sensitivity check index (QUICKI) and fasting plasma insulin showed a strong predictive 
power for diabetes (182, 206). However, Matsuda ISI and other tissue-specific IR indices 
(Adipocyte IR and Liver IR) were not included, and the ability of markers of tissue level 
insulin resistance to predict worsening of glycemia and incident CVD events was not 
evaluated. In the follow-up study (Study I), Matsuda IR and Adipocyte IR had comparable 
ability to predict the worsening of glycemia after adjustment for confounding factors, 
including insulin secretion and baseline Glucose AUC, and compared to fasting insulin 
levels both indices were better predictors for of an increase in 2hPG and Glucose AUC. 
Matsuda IR, Adipocyte IR and fasting insulin levels also predicted incident type 2 diabetes 
and CVD events. 
 
IR is associated with lipid, lipoprotein and apolipoprotein alterations in both pre-diabetes 
and type 2 diabetes, namely high levels of TGs and ApoB, low levels of HDL cholesterol 
and the preponderance to sd-LDL particles.  
 
In our 5.9-year follow-up study (Study III), the ApoB/LDL cholesterol and ApoA1/HDL 
cholesterol ratios were the best predictors for higher glycemic levels (measured by Glucose 
AUC) and incident type 2 diabetes among non-diabetic men without statin treatment, 
whereas increased levels of HDL cholesterol and large HDL particles were preventive of 
deterioration of glycemia. These results are novel because previous studies have not 
investigated dyslipidemia markers as predictors for the worsening of glycemia. In Study III 
the ApoA1/HDL cholesterol and ApoB/LDL cholesterol ratios were the strongest predictors 
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of incident type 2 diabetes. Our study is in agreement with a previous study in a Taiwanese 
population that showed that the ApoA1/HDL ratio was associated with incident type 2 
diabetes (274). High HDL cholesterol level was preventive of type 2 diabetes, but ApoA1 
levels alone did not significantly predict incident type 2 diabetes in our study. Another 
study in predominantly Caucasian population showed that high levels of HDL cholesterol, 
and high HDL cholesterol/ApoA1 and HDL cholesterol/ApoA-II ratios were strongly and 
independently related to a lower risk of future type 2 diabetes (116). In our study ApoB 
concentration did not associate with incident type 2 diabetes, in contrast to a study in an 
aboriginal Canadian population (273). Additionally, the ApoB/LDL cholesterol ratio was 
predictive for type 2 diabetes in a study of 2466 Turkish adults (272). The effects of 
lipoproteins and apoliporoteins on insulin sensitivity and insulin secretion were also 
evaluated in Study III. All lipoprotein traits, apoliporoteins (except for ApoA1) and their 
ratios predicted worsening of insulin sensitivity (Matsuda ISI) and insulin secretion (DI). 
These findings have not been previously published. These results suggest that both IR and 
impaired insulin secretion play a role in association of lipoproteins and apolipoproteins 
with the worsening of hyperglycemia and incident type 2 diabetes.  
6.3 GLYCEMIC AND NON-GLYCEMIC DETERMINANTS OF GLYCATED 
HEMOGLOBIN AND ITS ASSOCIATION WITH INSULIN SECRETION AND 
INSULIN SENSITIVITY (STUDY II) 
Erythrocytes are freely permeable to glucose, and therefore hemoglobin glycation occurs at 
a rate directly proportional to glucose concentration, and the rate of glycation is time -
dependent. However, several studies have proposed the concept that individuals glycate 
hemoglobin proteins at different rates (“glycation gap” or “hemoglobin glycation index”) 
(287, 288), and demonstrated the existence of glucose gradient across the erythrocyte 
membrane that might influence glycation of hemoglobin (289). This may at least in part 
explain the discordance between HbA1c levels and other measures of glycemia. Another 
explanation is that HbA1c levels may be also determined by factors not shared by glucose 
levels. Another potential source of variation might be related to analytical variables. 
Interpreting HbA1c levels in the presence of hemoglobinopathies that interfere with some of 
HbA1c assay (254), and other conditions that change erythrocyte ad turnover (e.g., chronic 
anemia, hemolysis, uremia etc.) can make HbA1c results unreliable (220). Iron deficiency, 
one of the most common nutritional deficiency, and depletion of vitamin B12 might be 
responsible for a considerable increase in HbA1c levels due to prolonged erytrocyte lifespan. 
However, HbA1c can be mesured accurately, if the appropriate method is used (209). Since 
HbA1c is the one of the most widely used biomarkers of type 2 diabetes and hyperglycemia, 
it is important to get a better insight in factors determining HbA1c levels especially in non-
diabetic individuals, and the mechanisms through which they act.  
 
In Study II, age, FPG, hs-CRP, the GRS and smoking were the most important determinants 
of HbA1c levels among non-diabetic individuals, explaining 14% of variance in HbA1c levels. 
A full predictive model with 18 glycemic and non-glycemic determinants explained 17% of 
the variance in HbA1c levels. Insulin secretion (DI) and insulin sensitivity (Matsuda ISI) 
contributed only less than 2% to the explained variance. In a previous study glucose 
intolerance explained only one third of variance in HbA1c levels (237). In Study II 
correlations between HbA1c and glycemic variables (Matsuda ISI, DI, FPG and 2hPG) were 
weaker than corresponding correlations of FPG, 2hPG, and measurements of glycemia FPG 
and 2hPG together explained only 4.3% of total variance in HbA1c levels. The conclusions 
from Study II are in agreement with a study of 2212 randomly selected non-diabetic adults 
reporting only moderate correlations of glucose with HbA1c (238). Similarly to our results, a 
previous study of Dutch adults without type 2 diabetes reported that a substantial part of 
variance in HbA1c was explained by non-glycemic factors including age, gender, BMI (290). 
41 
 
However, in type 2 diabetes HbA1c levels are mostly dependent on glucose levels, as was 
the case also in Study II in participants with newly-diagnosed type 2 diabetes. 
 
The heritability of HbA1c is estimated to be between 40-60% (234, 235). A genome-wide 
association study identified 11 single nucleotide polymorphisms (SNPs) in 10 different 
genetic loci that were associated with HbA1c levels. These SNPs explained 2.4% of the 
variance in HbA1c levels and 5% of heritability of HbA1c (236). In Study II the GRS based on 
11 SNPs explained only 1.7% of variance in HbA1c levels, which is in agreement with a 
study of non-diabetic Dutch adults in which the GRS of 12 SNPs explained only 0.2% of the 
variance in HbA1c levels (290). 
 
Although HbA1c is one of diagnostic criteria for type 2 diabetes it is still unclear whether 
elevated levels of HbA1c within the non-diabetic range reliably reflect IR and impaired 
insulin secretion. A study of 1444 Japanese individuals demonstrated that increased levels 
of HbA1c were associated with impaired insulin secretion measured by the homeostasis 
model assessment of β-cell function (251). In contrast, another study including 61 Arabs 
reported an association of HbA1c with impaired insulin sensitivity (250), and a study of 522 
Mexican Americans reported an association with both impaired insulin secretion and 
insulin sensitivity (252). In Study II an increase in HbA1c poorly reflected decreases in 
insulin sensitivity (Matsuda ISI) and insulin secretion (DI) in non-diabetic individuals 
(these two explained 1.8% of the variation in HbA1c). In contrast, decreases in insulin 
secretion (-71% vs. -57%) and insulin sensitivity (-63% vs. -49%) were significantly larger in 
newly diagnosed patients with type 2 diabetes using the glucose criteria than the HbA1c 
criteria for diabetes. This finding is consistent with a previously published study which 
demonstrated that HbA1c levels between 5.7-6.4% have weaker correlations with insulin 
secretion, IR and other metabolic disorders than FPG and 2hPG (232).  
6.4 CONCLUDING REMARKS 
The search for reliable predictors of type 2 diabetes has been challenging, and ideal 
biomarkers for type 2 diabetes remain to be found. Ideally, a biomarker should identify 
people at high risk of developing type 2 diabetes beyond standard clinical and laboratory 
measurements. These markers are likely to regulate insulin secretion or insulin sensitivity, 
the two major pathophysiological disturbances in type 2 diabetes.  However, some of the 
markers in our study associated with the risk of type 2 diabetes, namely markers regulating 
lipids, lipoproteins and apolipoproteins, are not directly related to insulin secretion and 
insulin sensitivity. 
 
In future studies the identification of biomarkers predicting the conversion to type 2 
diabetes and risk of CVD should apply new approaches. Several additional new 
technologies are available. With proton nuclear magnetic resonance spectroscopy and the 
metabolomics approach it is possible to investigate the role of hundreds of metabolites (e.g. 
amino acids, ketone bodies, fatty acids, and other small-molecule metabolites) as 
biomarkers (“chemical fingerprints”) for the risk of type 2 diabetes and (291, 292). 
Additionally, mRNA gene expression in different tissues and proteomics can reveal gene 
products reflecting cellular function that could be potentially used as important biomarkers 
(293). Finally, epigenetics (promoter methylation and histone modification) markers are 
likely to be important predictors for type 2 diabetes and CVD (294, 295).  
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7. Summary 
The main findings of Studies I-III were as follows: 
 
 
Study I: Tissue-specific markers of IR predicted the worsening of glycemia, incident type 2 
diabetes and CVD events. Matsuda IR and Adipocyte IR were superior to fasting plasma 
insulin level in predicting the worsening of hyperglycemia. Liver IR was the best predictor 
for both incident type 2 diabetes and CVD events. 
 
 
Study II: Glycemic factors determined HbA1c levels poorly in the participants without type 
2 diabetes. Impaired insulin sensitivity and secretion only weakly contributed to the 
variance in HbA1c levels. HbA1c measurement gives substantially less information on the 
pathophysiological disturbances in glucose metabolism than the measurements of fasting 
plasma glucose and 2-hour plasma glucose. 
 
 
Study III: The apolipoprotein B/LDL cholesterol ratio was the strongest predictor of the 
worsening of glycemia, whereas the apolipoprotein A1/HDL cholesterol ratio was the 
strongest predictor of incident type 2 diabetes. Elevated concentrations of HDL cholesterol 
and large HDL particles were preventive of the worsening of glycemia and incident 
diabetes. The associations of lipoprotein traits, apolipoproteins and their ratios at baseline 
were associated with both insulin sensitivity and insulin secretion at the follow-up.  
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